The best health news search engine - My Health News » Medical News Today - Cancer/Oncology News » September 2010 - Bird flu, Avian influenza, Diabetes, Cholesterol, Caner, HIV

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/30/Relatives_Of_Young_Breast_Cancer_Patients_Could_Face_Increased_Risks_Of_Other_Cancers'

Relatives Of Young Breast Cancer Patients Could Face Increased Risks Of Other Cancers

Posted: September 30th, 2010, 8:00am CDT

Both male and female relatives of women diagnosed with breast cancer before the age of 35 are at an increased risk of other cancers even if they do not carry faulty BRCA1 and BRCA2 genes, scientists have discovered. The study*, published in the British Journal of Cancer** today (Wednesday) looked at the risks of breast and other cancers for the relatives of young women diagnosed with the disease...

Studies Reveal Trends In Survival, Targeted Breast Cancer Care

Posted: September 30th, 2010, 8:00am CDT

New studies on breast cancer screening, treatment, genetics and survival were released in advance of the 2010 Breast Cancer Symposium. The symposium is being held October 1-3, 2010, at the Gaylord National Hotel in Suburban Washington, DC (National Harbor, Md.)...

HJF Names Fellowship Award Winners

Posted: September 30th, 2010, 7:00am CDT

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has selected three promising Uniformed Services University of the Health Sciences (USU) doctoral students to receive fellowships for the 2010-2011 academic year. The program established in 1988, comprises two Henry M. Jackson Fellowships and one Val G. Hemming Fellowship...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/30/HUYA_Bioscience_And_Quintiles_Announce_Partnership_For_Phase_I_Development_Of_New_Cancer_Therapy'

HUYA Bioscience And Quintiles Announce Partnership For Phase I Development Of New Cancer Therapy

Posted: September 30th, 2010, 7:00am CDT

HUYA Bioscience International (HUYA), the leader in U.S.-China pharmaceutical co-development, and Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, announced an agreement to co-develop a new cancer drug, HBI-8000, sourced in China by HUYA...

Majority Of Canadians Worried About Cost Of Cancer Drugs

Posted: September 30th, 2010, 7:00am CDT

A large majority of Canadians - 85 per cent - say if they were diagnosed with cancer the cost of drugs would have a negative impact on their personal finances, according to poll results released today by the Canadian Cancer Society. Forty-seven per cent said the cost would have a 'major' negative impact on their finances...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/30/Women_With_Both_Triple_Negative_Breast_Cancer_And_BRCA_Mutations_Have_Lower_Risk_Of_Recurrence'

Women With Both Triple Negative Breast Cancer And BRCA Mutations Have Lower Risk Of Recurrence

Posted: September 30th, 2010, 6:00am CDT

Patients with triple negative breast cancer that also have mutations in the BRCA gene appear to have a lower risk of recurrence, compared to those with the same disease without the deleterious genetic mutation, according to researchers at The University of Texas MD Anderson Cancer Center...

Immunotherapy Boosts Cancer Survival In Children

Posted: September 30th, 2010, 6:00am CDT

Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions...

MicroRNA Panel Provides A More Precise Lung Cancer Diagnosis

Posted: September 30th, 2010, 6:00am CDT

A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer. Tina B. Edmonston, M.D., director of the clinical laboratory at Rosetta Genomics, Inc...

2010 AAO-HNSF New Research Daily Highlights: Wednesday, Sept. 29, 2010

Posted: September 30th, 2010, 6:00am CDT

The 2010 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, convened September 26-29, 2010, in Boston, MA...

Study: Racial Disparities In End-Of-Life Care

Posted: September 30th, 2010, 5:00am CDT

A new study in the Archives of Internal Medicine finds that black patients and white patients may not receive the same quality in end-of-life care. "Although all study participants were helped by conversations with their physicians, black patients' requests were not always taken into consideration," Los Angeles Times reports...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/30/Women_And_Infants_Provides_Fertility_Preservation_For_Childhood_Cancer_Survivors'

Women And Infants Provides Fertility Preservation For Childhood Cancer Survivors

Posted: September 30th, 2010, 4:00am CDT

It is estimated that 1 in 500 children will be diagnosed with a form of childhood cancer. Fortunately, with the use of aggressive treatment modalities, more than 75% of these children will be cured. Therefore, many of these children and parents are looking beyond the cancer at important quality of life issues and guiding their treatments to assure "normal" post-cancer survivorship...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/30/Compound_Discovered_In_Florida_Keys_Shows_Early_Promise_As_Colon_Cancer_Treatment'

Compound Discovered In Florida Keys Shows Early Promise As Colon Cancer Treatment

Posted: September 30th, 2010, 4:00am CDT

A chemical compound made from a type of bacteria discovered in the Florida Keys by a University of Florida pharmacy researcher has shown effectiveness in fighting colon cancer in preclinical experiments...

IU Researchers: Chemotherapy Alters Brain Tissue In Breast Cancer Patients

Posted: September 30th, 2010, 4:00am CDT

Researchers at the Indiana University Melvin and Bren Simon Cancer Center have published the first report using imaging to show that changes in brain tissue can occur in breast cancer patients undergoing chemotherapy. The cognitive effects of chemotherapy, often referred to as "chemobrain," have been known for years...

Hopes For Better Survival And Quality Of Life For Kids With Neuroblastoma

Posted: September 30th, 2010, 4:00am CDT

Two new studies published in a leading journal this week suggest new ways to improve survival and quality of life for children with high and medium risk neuroblastoma, an aggressive childhood cancer that attacks the sympathetic nervous system, the nerves that respond to stress. You can read about the two studies in the 30 September issue of the New England Journal of Medicine...

CA's Tobacco Controls Result In Lower Lung Cancer Rates

Posted: September 30th, 2010, 3:00am CDT

A study led by researchers at the University of California, San Diego shows that California's 40 year-long tobacco control program has resulted in lung cancer rates that are nearly 25 percent lower than other states. "The consistency in the trends from cigarette sales and population surveys was reassuring" said John P. Pierce, PhD, Sam M...

Sneaking Spies Into A Cell's Nucleus

Posted: September 30th, 2010, 2:00am CDT

Duke University bioengineers have not only figured out a way to sneak molecular spies through the walls of individual cells, they can now slip them into the command center -- or nucleus -- of those cells, where they can report back important information or drop off payloads...

Individual Mutations Are Very Slow To Promote Tumor Growth

Posted: September 30th, 2010, 2:00am CDT

Individual cancer-causing mutations have a minute effect on tumor growth, increasing the rate of cell division by just 0.4 percent on average, according to new mathematical modeling by scientists at Harvard University, Johns Hopkins University, and other institutions...

Incidental Medical Imaging Test Findings, What Is The Correct Approach?

Posted: September 29th, 2010, 11:00am CDT

In over one third of all cases in which patients partake in a medical imaging procedure, an actual 40% display tumors or infections that are unrelated to the original need for the initial imaging...

New Prostate Cancer Test Could Be 90 Per Cent Accurate

Posted: September 29th, 2010, 11:00am CDT

According to early findings of a pilot study presented at a conference in the US this week, the controversy surrounding prostate cancer screening could be about to change: a UK company has developed a panel of biomarkers that appears to distinguish samples of prostate cancer from samples of benign prostate disease and healthy prostate tissue 90 per cent of the time, ...

Intrauterine Device May Deliver Hormones And Halt Endometrial Cancer

Posted: September 29th, 2010, 10:00am CDT

An intrauterine device (IUD) - the coil contraceptive device - may be used to delay endometrial cancer, European researchers reveal in an article published in Annals of Oncology. Endometrial cancer is also known as cancer of the uterus or cancer of the womb...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/29/Draft_NICE_Guidance_Recommends_A_New_Treatment_For_Certain_Patients_With_Metastatic_Gastric_Cancer'

Draft NICE Guidance Recommends A New Treatment For Certain Patients With Metastatic Gastric Cancer

Posted: September 29th, 2010, 9:00am CDT

In its latest draft guidance, NICE has recommended trastuzumab (Herceptin, Roche Products) for certain patients with metastatic gastric cancer who have high levels of human epidermal growth factor receptor 2 (HER2). HER2 is a protein found on the surface of some cancer cells. Gastric cancer cells have higher levels of the HER2 protein than normal cells...

Cancer Follow-Ups Are A Waste Of Time

Posted: September 29th, 2010, 8:00am CDT

The current follow-up system for cancer patients is a waste of time and needs to be completely overhauled, according to Jane Maher, Chief Medical Officer at Macmillan Cancer Support writing for BBC Scrubbing Up...

Exercise Reduces Risk Of Developing Womb Cancer

Posted: September 29th, 2010, 8:00am CDT

Women who exercise and keep active are around 30 per cent less likely to develop womb cancer than couch potatoes - according to a new study published in the British Journal of Cancer today...

ZIOPHARM Granted Japanese Patent For Darinaparsin

Posted: September 29th, 2010, 7:00am CDT

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced that the Japanese Patent Office has issued a patent, Patent No...

c-Met May Be A Biomarker For Metastatic Hepatocellular Carcinoma

Posted: September 29th, 2010, 6:00am CDT

Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development...

Under Development - A Method To Detect Bladder Cancer Earlier

Posted: September 29th, 2010, 6:00am CDT

Scientists may have discovered a way to diagnose bladder cancer at its earliest and, therefore, most treatable stages by measuring the presence or absence of microRNA using already available laboratory tests. "Measuring expressions of microRNA in bodily fluid represents a very promising tool with widespread implications for screening," said Liana Adam, M.D., Ph.D...

Novel Biomarker May Predict Response To New VEGF Receptor Inhibitor

Posted: September 29th, 2010, 6:00am CDT

Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib. This is possible, the researchers from AVEO Pharmaceuticals, Inc. said, because they have used a new way of creating animal tumor models that mimic tumor variation seen in humans...

Taking The Fingerprint Of Basal Breast Cancer, Australia

Posted: September 29th, 2010, 6:00am CDT

Australian researchers have used sophisticated new protein screening technology to profile basal breast cancer, a particularly aggressive sub-type of breast cancer, identifying specific targets for future treatments. Basal breast cancers represent between 10 and 27% of all breast cancers, depending on the population sampled...

Provectus Reports Encouraging Data On Visceral Metastases Presented At ASCO

Posted: September 29th, 2010, 5:00am CDT

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT) , a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr...

$Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/29/Seattle_Genetics_And_Millennium_Announce_Positive_Top_Line_Brentuximab_Vedotin__Data_From_Pivotal_Trial_In_Relapsed_And_Refractory_Hodgkin_Lymphoma'$

Seattle Genetics And Millennium Announce Positive Top-Line Brentuximab Vedotin Data From Pivotal Trial In Relapsed And Refractory Hodgkin Lymphoma

Posted: September 29th, 2010, 4:00am CDT

Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), announced positive top-line results from the pivotal trial of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/29/New_Study_Shows_Newer_Breast_Cancer_Treatments__Along_With_Improved_Early_Detection__Are_Key_To_Fewer_Breast_Cancer_Deaths'

New Study Shows Newer Breast Cancer Treatments, Along With Improved Early Detection, Are Key To Fewer Breast Cancer Deaths

Posted: September 29th, 2010, 4:00am CDT

A new study over the usefulness of mammography confirms what most people in the breast cancer community already know. Mammograms are one tool in the breast cancer cache: better early detection, widespread awareness and more effective treatments all play a role in reducing deaths from the disease, according to Susan G. Komen for the Cure®...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/29/Genta_Initiates_New_Trial_Of_Tesetaxel__The_Leading_Clinical_Stage_Oral_Taxane__In_Patients_With_Advanced_Bladder_Cancer'

Genta Initiates New Trial Of Tesetaxel, The Leading Clinical-Stage Oral Taxane, In Patients With Advanced Bladder Cancer

Posted: September 29th, 2010, 4:00am CDT

Genta Incorporated (OTCBB: GETA.OB) announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development...

Sorting Through The Mammography Controversy

Posted: September 29th, 2010, 4:00am CDT

A year after a government panel revised its recommendations for breast cancer screening, many professional organizations have not followed suit. Where does this leave the average woman? "Experts agree mammography saves lives, and all major organizations still recommend regular mammograms...

Turmeric Could Provide Recipe For Fight Against Cancer

Posted: September 29th, 2010, 3:00am CDT

Scientists at the University of Leicester, funded by Hope Against Cancer, are pioneering the use of a common curry cooking ingredient to target cancer cells. The research in the University Department of Cancer Studies and Molecular Medicine is making use of actual tissue from tumours extracted from patients undergoing surgery...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/29/Nearly_80%_Of_Men_Are_Unaware_Of_Their_Breast_Cancer_Risk_Despite_Having_A_Family_History_Of_The_Disease'

Nearly 80% Of Men Are Unaware Of Their Breast Cancer Risk Despite Having A Family History Of The Disease

Posted: September 29th, 2010, 3:00am CDT

A study, published in the October issue of the American Journal of Nursing (AJN), revealed that nearly 80% of men are unaware of their breast cancer risk despite having a family history of the disease. One hundred percent of respondents also reported that their healthcare provider did not discuss the disease with them...

A New Way Of Reversing Certain Cancers

Posted: September 29th, 2010, 3:00am CDT

Australian and American scientists have found a way of shrinking tumours in certain cancers - a finding that provides hope for new treatments. The cancers in question are those caused by a new class of genes known as 'microRNAs', produced by parts of the genome that, until recently, were dismissed as 'junk DNA'...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/29/CEL_SCI_Corporation_Receives_Russian_Federation_Ethical_Council_Approval_For_Multikine_Phase_III_Clinical_Trial_In_Head_And_Neck_Cancer'

CEL-SCI Corporation Receives Russian Federation Ethical Council Approval For Multikine Phase III Clinical Trial In Head And Neck Cancer

Posted: September 29th, 2010, 3:00am CDT

CEL-SCI Corporation (NYSE AMEX:CVM) announced today it has received approval from the Ethical Council Affiliated with the Ministry of Healthcare and Social Development of the Russian Federation ("Ethical Council") for the Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer...

TAU Develops Innovative Software To Analyze And Manipulate Diseased Cells

Posted: September 29th, 2010, 2:00am CDT

About ten years ago, the discovery of microRNAs - tiny cellular molecules that regulate our genetic code - unlocked a world of scientific possibilities, including a deeper understanding of human disease. One new analytical technology is "deep sequencing," which gives scientists the ability to discover invaluable information about human diseases at a genetic level...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/29/Patient_Specific_Vaccines_For_Metastatic_Melanoma_May_Induce_Durable_Complete_Regression'

Patient-Specific Vaccines For Metastatic Melanoma May Induce Durable Complete Regression

Posted: September 29th, 2010, 2:00am CDT

Hoag Memorial Hospital Presbyterian recently announced encouraging clinical study results for patient-specific vaccine therapy to treat metastatic melanoma...

TCD Pharma Receives FDA IND Approval For New Cancer Drug

Posted: September 29th, 2010, 2:00am CDT

Traslational Cancer Drugs Pharma, S.L., ("TCD") has announced that the FDA has approved its Investigational New Drug (IND) application to begin a Phase I clinical study with its Choline Kinase Alpha inhibitor, TCD-717, for the treatment of solid tumors. The clinical development plan for TCD-717 is designed to expedite the drug candidate through the clinical development path...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/29/Personalized_Therapy_One_Step_Closer_To_Reality_With_The_Help_Of_Nanotechnology'

Personalized Therapy One Step Closer To Reality With The Help Of Nanotechnology

Posted: September 29th, 2010, 2:00am CDT

A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work. "We are making progress toward the goal of understanding how drugs work in different individuals," said Alice C. Fan, M.D., instructor in the division of oncology at Stanford University School of Medicine...

Surgery For Aggressive Prostate Cancer Gives 92% 10-year Survival Rate

Posted: September 28th, 2010, 8:00am CDT

Patients with the most aggressive form of prostate cancer who have surgery - radical prostatectomy - were found to have a 10-year cancer-specific survival rate of 92%, which is high, and a 77% overall survival rate, according to researchers from the Fox Chase Cancer Center and the Mayo Clinic, USA...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/28/National_Cancer_Institute_Awards__13.6_Million_To_UNC_s_Carolina_Center_Of_Cancer_Nanotechnology_Excellence'

National Cancer Institute Awards $13.6 Million To UNC's Carolina Center Of Cancer Nanotechnology Excellence

Posted: September 28th, 2010, 7:00am CDT

The National Cancer Institute has awarded a five-year, $13.6 million grant to the University of North Carolina at Chapel Hill's Carolina Center of Cancer Nanotechnology Excellence (C-CCNE) based at the UNC Lineberger Comprehensive Cancer Center, for research to improve the diagnosis and treatment of cancer through applying/using advances in nanotechnology...

Panera Pink Ribbon Bagel Campaign Supports NJ Cancer Efforts

Posted: September 28th, 2010, 7:00am CDT

The return of a delectable signature item to Panera Bread® bakery-cafÃ© locations during the month of October will help New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center tackle a disease that affects one in eight U.S. women -- breast cancer...

MicroRNA To Combat Cancer

Posted: September 28th, 2010, 5:00am CDT

Researchers from the Queensland Institute of Medical Research, the Garvan Institute of Medical Research and the University of California-San Francisco have found a new way to kill cancer cells, opening the way for a new generation of cancer treatments...

Key Role Played By LIMK In Cancer Metastasis

Posted: September 28th, 2010, 4:00am CDT

Researchers have shown that LIM kinase (LIMK), an important regulator of actin cytoskeleton dynamics, plays a key role in cancer metastasis. The study appears online in The Journal of Cell Biology. Cancer metastasis is a multi-stage process that starts with the invasion of tumor cells into their surrounding tissue...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/28/Bone_Marrow_Transplant_Success_Rate_May_Be_Improved_By_Inhibiting_Cell_Signaling_Pathway'

Bone Marrow Transplant Success Rate May Be Improved By Inhibiting Cell Signaling Pathway

Posted: September 28th, 2010, 3:00am CDT

Identification of a molecular communications pathway that influences the mobilization of hematopoietic (blood) stem cells could lead to targeted therapies for improving bone marrow transplant success rates...

'Gold' Fish Thrive, Cancers Die

Posted: September 28th, 2010, 2:00am CDT

Rice University physicist Dmitri Lapotko has demonstrated that plasmonic nanobubbles, generated around gold nanoparticles with a laser pulse, can detect and destroy cancer cells in vivo by creating tiny, shiny vapor bubbles that reveal the cells and selectively explode them...

Surgery Found Effective For Patients With Aggressive Prostate Cancer

Posted: September 28th, 2010, 2:00am CDT

In one of the first studies to focus exclusively on the outcomes after treatment for patients with high-risk prostate cancer, researchers have found that surgery provides high survival rates...

Brentuximab Vedotin (SGN-35) Shrinks Tumors In 75% Of Hodgkin Lymphoma Patients

Posted: September 27th, 2010, 10:00am CDT

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate that targets CD30 was found to shrink tumors in 75% of 102 patients with relapsed or refractory Hodgkin lymphoma in a pivotal trial. Brentuximab Vedotin was developed by Seattle Genetics Inc. and The Takeda Oncology Company, part of Takeda Pharmaceutical Company Limited...

Scientists Discover How 'Winning Cell' Guides Blood Vessel Growth

Posted: September 27th, 2010, 5:00am CDT

Cancer Research UK scientists have found for the first time that cells compete with each other to guide the 'sprouting' and growth of blood vessels, and they have identified how the balance of key receptors on cells control this process. Their research is published in Nature Cell Biology today. New blood vessels in most tumours form by sprouting - like the way branches grow on trees...

A New Look At Racial Disparities In Head And Neck Cancer

Posted: September 27th, 2010, 4:00am CDT

Head and neck cancer outcomes associated with race may be more closely linked to social and behavioral factors than biological differences, especially for African Americans, according to a new Henry Ford Hospital study...

New Research Highlights At The 2010 AAO-HNSF Sunday, Sept. 26, 2010

Posted: September 27th, 2010, 4:00am CDT

The 2010 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, convened September 26-29, 2010, in Boston, MA...

2010 AAO-HNSF Miniseminars Summary

Posted: September 27th, 2010, 4:00am CDT

The 2010 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, convened September 26-29, 2010, in Boston, MA. AAO-HNSF Academic Bowl Presenters: J...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/27/Siemens_Now_Offers_Complete_Oncology_Menu_On_Dimension_Vista_R__Intelligent_Lab_Systems'

Siemens Now Offers Complete Oncology Menu On Dimension Vista(R) Intelligent Lab Systems

Posted: September 27th, 2010, 4:00am CDT

Siemens Healthcare Diagnostics' LOCI CA 125II, CA 15-3 and CA 19-9 have been CE Marked for use on the Dimension Vista Intelligent Lab Systems, which now offer a complete panel of oncology assays outside the U.S...

Molecule Identified That Increases Survival Of Stomach Cancer Patients

Posted: September 26th, 2010, 4:00am CDT

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. JesÃºs GarcÃa-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/26/Johns_Hopkins_Researchers_Publish_Results_Of_Study_Evaluating_Multiplex_Assay_For_Detection_Of_Common_NPM1_Mutations'

Johns Hopkins Researchers Publish Results Of Study Evaluating Multiplex Assay For Detection Of Common NPM1 Mutations

Posted: September 26th, 2010, 3:00am CDT

Asuragen, Inc. announced the results of a collaborative study with scientists at Johns Hopkins University School of Medicine evaluating a RNA-based assay for the rapid, sensitive and multiplex detection of common NPM1 mutations. The study results were published in the September issue of the Journal of Molecular Diagnostics...

17th Annual Black America's Dialogue On Health Conference To Focus On Cancer

Posted: September 26th, 2010, 3:00am CDT

The National Black Caucus of State Legislators (NBCSL) will host the 17th Annual installment of the Black America's Dialogue on Health series October 1st at the Hyatt Regency Indianapolis...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/26/Sanofi_aventis_And_The_Belfer_Institute_Of_Applied_Cancer_Science_At_The_Dana_Farber_Cancer_Institute_Establish_Powerful_Alliance_In_Oncology'

Sanofi-aventis And The Belfer Institute Of Applied Cancer Science At The Dana-Farber Cancer Institute Establish Powerful Alliance In Oncology

Posted: September 26th, 2010, 3:00am CDT

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts, announced that they have entered into a collaboration and licence agreement to identify novel oncology targets for the development of new therapeutic agents directed at such targets and related biomarkers...

Scientists Reveal Gut Stem Cell Secrets

Posted: September 26th, 2010, 2:00am CDT

Cancer Research UK scientists have discovered that gut stem cells replace each other in a 'one in, one out' system, which is completely different to previously accepted theories. The research is published online in Science1. Before now, scientists thought that stem cells in the gut replace each other according to a predetermined system where the fate of the daughter cell is already decided...

NICE Opens Consultation On First Ever Guidelines To Tackle Ovarian Cancer

Posted: September 26th, 2010, 2:00am CDT

For the first time, national guidelines are being developed for the NHS in England and Wales to aid earlier diagnosis and promote more effective management and support specifically for women with ovarian cancer. Ovarian cancer is the fifth most common cancer in women with around 6,800 cases being diagnosed each year in the UK[1]...

Views Of Children With Cancer Help Inform Future Cancer Services

Posted: September 26th, 2010, 2:00am CDT

The experiences of children as young as seven years-old who are living with or beyond cancer have been shared with senior health officials to help inform future cancer services...

Routine Activity May Help Reduce Risk Of Invasive Breast Cancer

Posted: September 26th, 2010, 2:00am CDT

New evidence found that routine activity during the day at work or home may be important for breast cancer prevention...

Gut Stem Cells Replace Their Neighbors As They Are Lost, Surprising Scientists

Posted: September 25th, 2010, 7:00pm CDT

Scientists used to think that gut (intestine) stem cells replaced each other in a predetermined hierarchical way, so they were surprised to find that they, in fact, replace each other in a "one in, one out" system, according to new research published in the journal Science...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/25/The_Japanese_Cancer_Association_And_Debiopharm_Group%e2%84%a2present_The_JCA_Mauvernay_Award_To_Dr_Ogawa_And_Prof._Maeda'

The Japanese Cancer Association And Debiopharm Group™present The JCA-Mauvernay Award To Dr Ogawa And Prof. Maeda

Posted: September 25th, 2010, 4:00am CDT

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, today presented the 'The JCA-Mauvernay Award' to Doctor Seishi Ogawa from the University of Tokyo, for his research on cancer genome analysis and to Professor Shin Maeda from Yokohama Ci...

TU Delft To Help Cancer Patients

Posted: September 25th, 2010, 3:00am CDT

TU Delft's nuclear research reactor will be used as a back-up facility for the production of the radioactive isotope molybdenum-99, when supplies run out. Molybdenum-99 is widely used in hospitals in order to locate cancer. The substance is regularly in short supply because there are only five large commercial producers worldwide, and they all produce using older reactors...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/25/Researchers_Create_First_Molecule_Able_To_Block_Key_Component_Of_Cancer_Genes__On_Off_Switch'

Researchers Create First Molecule Able To Block Key Component Of Cancer Genes' On-Off Switch

Posted: September 25th, 2010, 3:00am CDT

In the quest to arrest the growth and spread of tumors, there have been many attempts to get cancer genes to ignore their internal instruction manual. In a new study, a team led by Dana-Farber Cancer Institute scientists has created the first molecule able to prevent cancer genes from "hearing" those instructions, stifling the cancer process at its root...

Legacy Beads Program Gives Pediatric Patients A Way To Cope With Treatment

Posted: September 25th, 2010, 3:00am CDT

Through the Legacy Beads Program at St. Jude Children's Research Hospital, patients collect colorful, glass beads that represent their experiences during treatment for cancer or other catastrophic childhood illnesses...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/25/Results_From_Argos_Therapeutics__Arcelis%e2%84%a2_Immunotherapy_Phase_2_Study_For_Treatment_Of_Renal_Cell_Carcinoma__RCC__Accepted_For_Presentation'

Results From Argos Therapeutics' Arcelis™ Immunotherapy Phase 2 Study For Treatment Of Renal Cell Carcinoma (RCC) Accepted For Presentation

Posted: September 25th, 2010, 3:00am CDT

Argos Therapeutics announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago. The study is an open-label Phase 2 trial that enrolled 25 patients with newly diagnosed metastatic clear cell RCC...

Cancer-Associated Long Non-Coding RNA Regulates Pre-mRNA Splicing

Posted: September 25th, 2010, 2:00am CDT

Researchers report this month that MALAT1, a long non-coding RNA that is implicated in certain cancers, regulates pre-mRNA splicing - a critical step in the earliest stage of protein production. Their study appears in the journal Molecular Cell...

'Blood Cancer Awareness Month' Recognized By U.S. House Of Representatives

Posted: September 24th, 2010, 8:00am CDT

The U.S. House of Representatives passed House Resolution 1433, declaring September 2010 as 'Blood Cancer Awareness Month.' The resolution helps raise awareness and support for issues affecting blood cancer patients within the halls of the Capitol...

Comic Books Featuring 'Super Heroes' Educate Young Men About Testicular Cancer

Posted: September 24th, 2010, 7:00am CDT

Comic books may help to educate young men and their partners about testicular cancer and its early symptoms and encourage them to do more self-screening, according to Ryerson University School of Fashion professor and comic book artist David Brame. Brame is the lead author of the study, Ain't Nothing Comic About It! Educating Young Men about Testicular Cancer: A Resource Development Project...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/24/Advanced_Targeting_Systems__Inc._Announces__3_Million_Award_From_National_Cancer_Institute'

Advanced Targeting Systems, Inc. Announces $3 Million Award From National Cancer Institute

Posted: September 24th, 2010, 7:00am CDT

Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases and for research into the function of biological systems, has been awarded $3 million from the National Cancer Institute (NCI)...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/24/US_And_EU_Regulatory_Submissions_For_Vandetanib_In_Advanced_Medullary_Thyroid_Cancer_Accepted_For_Review'

US And EU Regulatory Submissions For Vandetanib In Advanced Medullary Thyroid Cancer Accepted For Review

Posted: September 24th, 2010, 7:00am CDT

AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC)...

Selenium Associated With A Lower Risk Of Bladder Cancer

Posted: September 24th, 2010, 6:00am CDT

Scientists in Spain have found that adding a can of tuna or other fish to our shopping lists could help protect us against bladder cancerWorldwide, bladder cancer is one of the most common types of cancer, with an estimated 356,600 new cases of the disease diagnosed each year. Highest incidences are in Spain and Italy and it is the seventh most common cancer in the UK...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/24/Dana_Farber_Cancer_Institute_And_Sanofi_aventis_Establish_Cancer_Research_Alliance'

Dana-Farber Cancer Institute And Sanofi-aventis Establish Cancer Research Alliance

Posted: September 24th, 2010, 6:00am CDT

Dana-Farber Cancer Institute's Belfer Institute of Applied Cancer Science (Belfer Institute) and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that they have entered into a collaboration and license option agreement to identify and validate novel oncology targets for further discovery and development by sanofi-aventis of novel therapeutics agents directed to such targe...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/24/Advances_In_Cancer_And_Genetic_Testing__Molecular_Diagnostics__Medical_Ethics_And_Gender_Based_Disorders_To_Be_Focus_At_CAP__10'

Advances In Cancer And Genetic Testing, Molecular Diagnostics, Medical Ethics And Gender-Based Disorders To Be Focus At CAP '10

Posted: September 24th, 2010, 5:00am CDT

New science in cancer, genetic testing, molecular diagnostics, medical ethics, and gender-based disorders will be featured topics when nearly 1,200 pathologists gather at the Hyatt Regency Chicago on September 26 - 29 for the annual scientific meeting of the College of American Pathologists (CAP)...

New UF Study Examines Patient Treatment Decisions For Colorectal Cancer

Posted: September 24th, 2010, 5:00am CDT

A new University of Florida study will take an in-depth look at the factors involved in treatment decisions made by people with colorectal cancer. The study is funded by a $1.2 million grant from the Bankhead-Coley Florida Cancer Research Program, administered through the Florida Department of Health...

Improving Endpoints For Cancer Immunotherapy Clinical Trials

Posted: September 24th, 2010, 5:00am CDT

The Cancer Research Institute (CRI) Cancer Immunotherapy Consortium (CIC), the leading global initiative in advancing the emerging field of immuno-oncology, has proposed criteria for improved endpoints for cancer immunotherapy trials, which were published online on September 8 in the Journal of the National Cancer Institute...

Patients With Cancer Who Stop Hospice Care Boost Health Care Costs

Posted: September 24th, 2010, 5:00am CDT

Researchers at Mount Sinai School of Medicine have found that the costs of care for patients with cancer who disenrolled from hospice were nearly five times higher than for patients who remained with hospice. Patients who disenroll from hospice are far more likely to use emergency department care and be hospitalized...

New Signaling Pathway That Controls Cell Development And Cancer

Posted: September 24th, 2010, 5:00am CDT

Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia...

Texas Tech Chemist To Study Cell Death With $520,000 NIH Grant

Posted: September 24th, 2010, 5:00am CDT

A chemistry researcher at Texas Tech University received a $520,000 grant to find better methods of studying cell death that could lead to more useful medications for ailments such as heart disease and cancer...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/24/New_Study_Finds_That_The_Risk_Of_Cancer_In_People_Using_Insulin_Is_Highest_At_The_Start_Of_Insulin_Treatment_And_Decreases_Over_Time'

New Study Finds That The Risk Of Cancer In People Using Insulin Is Highest At The Start Of Insulin Treatment And Decreases Over Time

Posted: September 24th, 2010, 4:00am CDT

Researchers from Steno Diabetes Center in Denmark have performed the largest registry linkage study to date focused on diabetes, cancer and insulin use. The study followed the total Danish population, currently 5.5 million people, during 13 years assessing the relationship between duration of insulin use and the occurrence of cancer...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/24/Cell_Division_Typically_Associated_With_Cancer_May_Also_Protect_The_Liver_From_Injury'

Cell Division Typically Associated With Cancer May Also Protect The Liver From Injury

Posted: September 24th, 2010, 3:00am CDT

Researchers at Oregon Health & Science University have discovered that a form of cell division typically associated with cancer called multipolar mitosis can yield diverse, viable cells capable of protecting the liver from injury and poisonous substances, such as pesticides, carcinogens or drugs. Their findings are published online in the journal Nature...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/24/Jonsson_Cancer_Center_Researchers_Discover_New_Signaling_Pathway_That_Controls_Cell_Development_And_Cancer'

Jonsson Cancer Center Researchers Discover New Signaling Pathway That Controls Cell Development And Cancer

Posted: September 24th, 2010, 2:00am CDT

Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia...

Toward The First Nose Drops To Treat Brain Cancer

Posted: September 24th, 2010, 2:00am CDT

Scientists are reporting the development and successful initial testing of a new form of methotrexate - the mainstay anticancer drug - designed to be given as nose drops rather than injected. It shows promise as a more effective treatment for brain cancer, they say. The report appears in ACS' Molecular Pharmaceutics, a bi-monthly journal...

Majority Of Women Have Sexual Function Problems After Breast Cancer

Posted: September 23rd, 2010, 10:00am CDT

About 70% of women have sexual problems after breast cancer, researchers in Australia revealed in a new study published in the Journal of Sexual Medicine. Problems included libido, sexual satisfaction, concerns about body image which interfered with their sex drive, and menopausal symptoms linked to breast cancer treatments...

ImmunoGen, Inc. Announces Start Of SAR566658 Clinical Testing

Posted: September 23rd, 2010, 5:00am CDT

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, announced the start of clinical testing with SAR566658...

'Synthetic Lethality' Strategy Improves Molecularly Targeted Cancer Therapy

Posted: September 23rd, 2010, 3:00am CDT

Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time...

Fertility Preservation For Cancer Patients Gets A Boost In The Bay

Posted: September 22nd, 2010, 8:00am CDT

In efforts to increase awareness of fertility preservation options for cancer patients whose treatment may jeopardize their future fertility, Reproductive Science Center of the San Francisco Bay Area (RSC) created the Sharing Hope Program in partnership with Lance Armstrong's LIVESTRONG Foundation...

Stress Before Cancer Therapy Could Help Deadly Cells Survive Treatment

Posted: September 22nd, 2010, 6:00am CDT

Patients who experience physical or psychological stress including rigorous exercise one or two days before a cancer treatment might be unknowingly sabotaging their therapy, new research suggests...

Protein Helps Cells Rapidly Repair Damage Due To Mechanical Stress

Posted: September 22nd, 2010, 6:00am CDT

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have discovered that a protein, zyxin, is necessary for the maintenance and repair of the cell's cytoskeleton, or internal framework, which serves as the muscle and bone of the cell. The research has implications for cancer, as well as other diseases, since alterations in the cytoskeleton are often associated with disease...

Pancreas Publishes NANETS Guidelines For Neuroendocrine Tumors

Posted: September 22nd, 2010, 4:00am CDT

Neuroendocrine tumors (NETs) are a group of rare cancers that pose unique challenges in diagnosis and treatment. In a recent issue of Pancreas, official journal of the American Pancreatic Association, presents the newly developed consensus guidelines of the North American Neuroendocrine Tumor Society (NANETS)...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/22/Celldex_Therapeutics_Announces_Initiation_Of_Randomized_Phase_2b_Clinical_Trial_Of_CDX_011_In_Advanced_Breast_Cancer'

Celldex Therapeutics Announces Initiation Of Randomized Phase 2b Clinical Trial Of CDX-011 In Advanced Breast Cancer

Posted: September 22nd, 2010, 4:00am CDT

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients...

$Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/22/Micromet_Initiates_Phase_2_Trial_Of_Blinatumomab_In_Adult_Patients_With_Relapsed_Refractory_Acute_Lymphoblastic_Leukemia'$

Micromet Initiates Phase 2 Trial Of Blinatumomab In Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Posted: September 22nd, 2010, 4:00am CDT

Micromet, Inc. (NASDAQ: MITI) announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells...

War On Cancer Produces Collateral Damage To The Heart

Posted: September 22nd, 2010, 3:00am CDT

For the past two decades, cancer therapy has become more sophisticated and effective, resulting in an ever-expanding group of long-term cancer survivors. There is also a growing awareness of the potentially negative effects of cancer treatment on the heart and the management of cardiac disease during and after cancer therapy...

The AACR To Host Molecular Diagnostics Conference

Posted: September 22nd, 2010, 3:00am CDT

The American Association for Cancer Research will host its Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development from Sept. 27-30, 2010, at the Sheraton Denver Downtown in Denver, Colo. Recent advances in genomics, proteomics, molecular imaging and other new technologies are leading to a molecularly based reclassification of cancer...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/22/Effects_Of_Chemoradiation_Therapy_By_Using_Capecitabine_On_Gastric_Cancer_Patients'

Effects Of Chemoradiation Therapy By Using Capecitabine On Gastric Cancer Patients

Posted: September 22nd, 2010, 2:00am CDT

Gastric cancer is a major cause of cancer deaths in the world. The outcome of large gastric tumors and those with lymph node involvement remains poor after surgical resection. The optimal adjuvant therapy after surgical resection remains to be determined. The most common strategies in the adjuvant treatment of gastric cancers include fluoropyrimidine-based chemotherapy with or without radiation...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/21/Reconstruction_After_Mastectomy_And_Radiation__When_Are_The_Right_Times_For_Each_'

Reconstruction After Mastectomy And Radiation; When Are The Right Times For Each?

Posted: September 21st, 2010, 1:00pm CDT

An increasing number of women are undergoing mastectomy as a treatment for breast cancer or as a means of prevention. After breast cancer patients receive a mastectomy, a partial or full removal of the breast, often radiation therapy is required...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/21/Breast_Cancer_Sentinel_Node_Surgery_Is_An_Effective_Alternative_To_Auxiliary_Lymph_Node_Dissection'

Breast Cancer Sentinel Node Surgery Is An Effective Alternative To Auxiliary Lymph Node Dissection

Posted: September 21st, 2010, 11:00am CDT

Auxiliary lymph node dissection, or ALND, has often been the surgery chosen by practioners to curb growth of breast cancer in patients. However, a recent study based on surgical trials, and published Online First in The Lancet Oncology publication, notes that SLN (sentinel node surgery) has equal success and is also a safe and effective treatment...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/21/Breast_Cancer_Sentinel_Node_Surgery_Is_An_Effective_Alternative_To_Axillary_Lymph_Node_Dissection'

Breast Cancer Sentinel Node Surgery Is An Effective Alternative To Axillary Lymph Node Dissection

Posted: September 21st, 2010, 11:00am CDT

Axillary lymph node dissection, or ALND, has often been the surgery chosen by practioners to curb growth of breast cancer in patients. However, a recent study based on surgical trials, and published Online First in The Lancet Oncology publication, notes that SLN (sentinel node surgery) has equal success and is also a safe and effective treatment...

Sunless Tanning Products May Protect Skin From Cancer And Burns

Posted: September 21st, 2010, 10:00am CDT

A recent study found that approximately 10% of American teens use sunless tanning products. An article in this week's Archives of Dermatology suggests promoting sunless tanning products to adult females may help reduce the risks of developing skin cancers and burns, now that ultraviolet radiation exposure has been upgraded to the highest cancer risk category...

Why Breast Cancer Patients Feel Pretty

Posted: September 21st, 2010, 8:00am CDT

blue sky scrubs are making cancer patients feel good about themselves. Through Project Blue Sky, blue sky scrubs is able to provide patients with a fashion forward way to cover the most outward sign of sickness, hair loss. With every purchase, blue sky scrubs sends a free to hat to either a cancer patient at MD Anderson or the purchasing customer...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/21/Surgeon_Develops_Revolutionary_Endoscopic_Procedure_For_Removal_Of_Most_Difficult_To_Access_Brain_Tumor'

Surgeon Develops Revolutionary Endoscopic Procedure For Removal Of Most Difficult To Access Brain Tumor

Posted: September 21st, 2010, 8:00am CDT

One of the most difficult-to-remove tumors located deep in the midbrain area can now be safely excised thanks to the work of one Los Angeles surgeon. Hrayr Shahinian, M.D., medical director of The Skull Base Institute in Los Angeles, has developed a minimally invasive approach to removing pineal tumors so called as they are shaped like pine cones...

Demethylation Mechanism Pinpointed In APC Gene Mutants

Posted: September 21st, 2010, 3:00am CDT

Colon cancer is the second most common cancer in the United States and causes more than 50,000 deaths each year. It has been known for some time that mutations in the APC gene occur in more than 85 percent of all sporadic colon cancers...

Targeted Therapy Decreases Progression Rate In Thyroid Cancer

Posted: September 21st, 2010, 2:00am CDT

The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers at Mayo Clinic who are publishing findings of a phase II clinical trial in The Lancet Oncology. Additional audio and video resources, including excerpts from an interview with Dr...

Genentech Provides Update On Avastin For Advanced Breast Cancer

Posted: September 21st, 2010, 2:00am CDT

Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin® (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment...

$Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/21/Hybrigenics_Unveils_Positive_Final_Results_Of_Inecalcitol_Phase_IIa_Clinical_Study_In_Hormone_Refractory_Prostate_Cancer'$

Hybrigenics Unveils Positive Final Results Of Inecalcitol Phase IIa Clinical Study In Hormone-Refractory Prostate Cancer

Posted: September 21st, 2010, 2:00am CDT

Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments, today announces the positive outcomes of clinical tolerance Phase IIa study of daily oral inecalcitol in combination with gold standard Taxotere(R) chemotherapy in hormone-refractory prostate cancer patients...

Ovarian Cancer Is Detected Promptly In Australia

Posted: September 20th, 2010, 7:00am CDT

In Australia, they say that most women with ovarian cancer are not diagnosed promptly or properly in general. However a recent study shows otherwise in most cases...

Mechanism Behind Demethylation Pinpointed In APC Gene Mutants

Posted: September 20th, 2010, 6:00am CDT

Colon cancer is the second most common cancer in the United States and causes more than 50,000 deaths each year. It has been known for some time that mutations in the APC gene occur in more than 85 percent of all sporadic colon cancers...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/20/Study_Challenges_Anecdotal_Evidence_Of_Diagnostic_Delay_In_Ovarian_Cancer__Australia'

Study Challenges Anecdotal Evidence Of Diagnostic Delay In Ovarian Cancer, Australia

Posted: September 20th, 2010, 6:00am CDT

Most women with ovarian cancer in Australia are investigated and diagnosed promptly, despite anecdotal suggestions to the contrary, according to research published in the Medical Journal of Australia. However, delays in clinical diagnosis are more common for women with lower incomes, those living in remote areas, and those with abdominal or bowel symptoms...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/20/AICR_s_New__Breast_Cancer_Prevention_Pack__Offers_Health_Fair_Organizers_The_Science_And_Strategies_To_Prevention'

AICR's New "Breast Cancer Prevention Pack" Offers Health Fair Organizers The Science And Strategies To Prevention

Posted: September 20th, 2010, 5:00am CDT

To support October's Breast Cancer Awareness Month, the American Institute for Cancer Research (AICR) is now offering the AICR Breast Cancer Prevention Pack, one convenient packet of science-based materials to help women prevent breast cancer through basic lifestyle changes...

First Australian Study Into Diagnosis Of Ovarian Cancer

Posted: September 20th, 2010, 4:00am CDT

For the first time the diagnostic experience of Australian woman with ovarian cancer, from their first trip to a doctor to diagnosis, has been studied. Researchers from the Queensland Institute of Medical Research (QIMR), The National Breast and Ovarian Cancer Centre and The University of Queensland, interviewed almost 1,500 women as part of the Australian Ovarian Cancer Study...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/20/Boehringer_Ingelheim_Initiates_Phase_III_Clinical_Trial_With_Novel_Oral_Agent_In_Advanced_Breast_Cancer'

Boehringer Ingelheim Initiates Phase III Clinical Trial With Novel Oral Agent In Advanced Breast Cancer

Posted: September 20th, 2010, 4:00am CDT

Boehringer Ingelheim announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer...

BRCA1 Breast Cancer Risk Linked To Other Genes

Posted: September 20th, 2010, 4:00am CDT

A large international team of researchers led by the Mayo Clinic in the US has discovered that some individuals whose risk of breast cancer may be increased by carrying a variant of the BRCA1 gene may also possess other gene variants that can modify that risk, bringing closer the day when it will be possible to determine individual risk for breast cancer in carriers of BRCA1...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/19/ImmunoCellular_Therapeutics_Selects_Averion_International_Corp._To_Conduct_Phase_II_Glioblastoma_Study'

ImmunoCellular Therapeutics Selects Averion International Corp. To Conduct Phase II Glioblastoma Study

Posted: September 19th, 2010, 3:00am CDT

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies (the "Company"), has announced that it has contracted with the clinical research organization (CRO) Averion International Corp...

PCF Encouraged By Introduction Of New Prostate Cancer Legislation

Posted: September 19th, 2010, 3:00am CDT

As hundreds of prostate cancer researchers, advocates and supporters Advance on Washington this week and push for more progress in fighting the disease, the Prostate Cancer Foundation applauds the prostate cancer legislation introduced on Tuesday by Senator Jon Tester of Montana...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/19/Vidacare_s_OnControl%e2%84%a2_Bone_Marrow_Biopsy_And_Aspiration_System_Hits_Growth_Milestone'

Vidacare's OnControl™ Bone Marrow Biopsy And Aspiration System Hits Growth Milestone

Posted: September 19th, 2010, 3:00am CDT

In just six months, Vidacare Corporation's OnControl™ Bone Marrow System hit its first significant growth milestone and is now available in 50 health care centers across the United States...

Link Between Father Absence And Earlier Puberty Among Certain Girls

Posted: September 19th, 2010, 2:00am CDT

Girls in homes without a biological father are more likely to hit puberty at an earlier age, according to a new study led by researchers at the University of California, Berkeley's School of Public Health...

Partnership On National Database Addresses Cancer In NJ

Posted: September 19th, 2010, 2:00am CDT

A new partnership between The Cancer Institute of New Jersey (CINJ), the state's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, and the New Jersey Department of Health and Senior Services (NJDHSS) will create a Center of Excellence for Cancer Surveillance to help track, examine, prevent and control cancer...

Pazopanib Shows Promising Results For Advanced Thyroid Cancer Patients

Posted: September 18th, 2010, 10:00am CDT

A Phase II clinical trial with Pazopanib for the treatment of advanced differentiated thyroid cancer which stops tumor blood vessel growth had promising results...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/18/Targeted_Therapy_Substantially_Decreases_Progression_Rate_In_Patients_With_An_Aggressive_Form_Of_Thyroid_Cancer'

Targeted Therapy Substantially Decreases Progression Rate In Patients With An Aggressive Form Of Thyroid Cancer

Posted: September 18th, 2010, 3:00am CDT

The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers at Mayo Clinic who are publishing findings of a phase II clinical trial in The Lancet Oncology The researchers studied 37 patients with the most aggressive form of this cancer -- developing in less than 5 percent of patients w...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/18/Emory_Researchers_Say_Chronic_Diseases_A_Global_Problem_Requiring_Global_Solutions'

Emory Researchers Say Chronic Diseases A Global Problem Requiring Global Solutions

Posted: September 18th, 2010, 2:00am CDT

Policymakers should increase their sense of urgency to stop the global spread of chronic diseases such as heart disease, cancer and diabetes that threaten the health and economies of industrialized and developing nations alike, Emory University global health researchers say. Writing in the current issue of The New England Journal of Medicine, authors K. M...

Report Card Delivered On UK Cancer Plans

Posted: September 17th, 2010, 8:00am CDT

In a new report released today (Friday) cancer experts and health professionals outline the importance of cancer plans and reveal the gains and gaps between the different nations' cancer care...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/17/Uncertainty_Over_Clinical_Benefit_Means_NICE_Says_No_To_Ovarian_Cancer_Drug_In_Draft_Guidance'

Uncertainty Over Clinical Benefit Means NICE Says No To Ovarian Cancer Drug In Draft Guidance

Posted: September 17th, 2010, 8:00am CDT

The National Institute for Health and Clinical Excellence (NICE) remains unable to recommend trabectedin (Yondelis, PharmaMar) for relapsed ovarian cancer due to continued concerns over how well the drug works compared with the most commonly-used treatments, according to further draft guidance published today (17 September)...

BCM-95 Demonstrates Superior Anti-Inflammatory Effects

Posted: September 17th, 2010, 6:00am CDT

Top researchers at the Gastrointestinal Cancer Research Lab at Baylor University Medical Center in Dallas are exploring the clinical applications of BCM-95®, a new patented extract of curcumin with unprecedented potency, and bioavailability...

Enzyme Responsible For Brain Tumors Discovered

Posted: September 17th, 2010, 6:00am CDT

Tom Wurdinger, a Dutch researcher who is connected to Harvard (Boston) and the VUmc Cancer Center in Amsterdam, has discovered the enzyme playing a very important role in the return of malign brain tumor after surgery and radiation. By making this enzyme inactive, the cancer cell can become disorganized and blow itself up...

Top Docs, Researchers Urge Congress To Step Up Childhood Cancer Fight

Posted: September 17th, 2010, 6:00am CDT

Panels of the nation's top cancer doctors and researchers joined Congressmen Michael McCaul (R-TX) and Joe Sestak (D-PA) at their Childhood Cancer Summit on Capitol Hill calling on Congress to increase funding in the fight against the disease...

Look Out For Early Cancer Signs, MDU Advises GPS

Posted: September 17th, 2010, 4:00am CDT

GPs are being advised to be alert to early symptoms and signs of malignancy, which according to a Medical Defence Union claims analysis, is the most frequent diagnosis to be missed or delayed in primary care...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/17/Novartis_JAK_Inhibitor_Provides_Marked_And_Durable_Clinical_Benefits_In_Patients_With_Myelofibrosis__A_Rare__Life_Threatening_Blood_Cancer'

Novartis JAK Inhibitor Provides Marked And Durable Clinical Benefits In Patients With Myelofibrosis, A Rare, Life-Threatening Blood Cancer

Posted: September 17th, 2010, 4:00am CDT

Results from a Phase I/II study of the Novartis Janus kinase (JAK) inhibitor with the investigational name INC424 (also known as INCB018424 and INCB18424) were published in The New England Journal of Medicine, demonstrating marked and durable clinical benefits in patients with myelofibrosis2. Novartis has licensed INC424 from Incyte for development and potential commercialization outside the US...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/17/Aetna_Supports_First_National_Study_On_Community_Based_Use_Of_Genetic_Tests_For_Cancer_Risk'

Aetna Supports First National Study On Community-Based Use Of Genetic Tests For Cancer Risk

Posted: September 17th, 2010, 4:00am CDT

Testing is available to help identify if a woman is likely to face one of her gender's worst fears: inherited breast and ovarian cancer...

Novel Target For Existing Drug May Improve Success Of Radiation Therapy

Posted: September 17th, 2010, 3:00am CDT

Scientists at Washington University School of Medicine in St. Louis have discovered a new drug target that could improve the effectiveness of radiation for hard-to-treat cancers. The finding, published in the Journal of the National Cancer Institute, focuses on the role of the enzyme cytosolic phospholipase A2 (cPLA2)...

Cancer Drug Not Good Value For The NHS, According To Latest Draft Guidance

Posted: September 17th, 2010, 2:00am CDT

The drug ofatumumab (Arzerra, GlaxoSmithKline) is not recommended for NHS use in patients with chronic lymphocytic leukaemia that is refractory (does not respond) to the drugs, fludarabine and alemtuzumab, in draft guidance published today (16 September)...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/17/Insufficient_New_Evidence_Available_On_Increased_Doses_Of_Imatinib_For_Treating_GIST_After_The_Standard_Dose_Fails'

Insufficient New Evidence Available On Increased Doses Of Imatinib For Treating GIST After The Standard Dose Fails

Posted: September 17th, 2010, 2:00am CDT

In its latest draft guidance NICE has not recommended imatinib (Glivec) at doses of 600 or 800 mg/day for people with unresectable and/or metastatic gastrointestinal stromal tumours (GIST) whose disease has progressed after treatment with 400 mg/day imatinib. Draft guidance is now with consultees, who have the opportunity to appeal against the proposed guidance...

MIT Researchers Discover An Unexpected Twist In Cancer Metabolism

Posted: September 16th, 2010, 4:00pm CDT

In a paper appearing in the Sept. 16 online edition of Science, Matthew Vander Heiden assistant professor of biology and member of the David H. Koch Institute for Integrative Cancer Research at MIT and researchers at Harvard University report a previously unknown element of cancer cells' peculiar metabolism...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/16/Stress_Significantly_Acclerates_Breast_Cancer_Metastasis_In_Mice__UCLA_Cancer_Researchers_Show_For_The_First_Time'

Stress Significantly Acclerates Breast Cancer Metastasis In Mice, UCLA Cancer Researchers Show For The First Time

Posted: September 16th, 2010, 8:00am CDT

Chronic stress acts as a sort of fertilizer that feeds breast cancer progression, significantly accelerating the spread of disease in animal models, researchers at UCLA's Jonsson Comprehensive Cancer Center have found...

Top Cancer Specialists Receive ESMO Awards

Posted: September 16th, 2010, 7:00am CDT

The European Society for Medical Oncology (ESMO) honors three eminent cancer specialists for their contribution to the advancement of medical research. The awards will be presented to Hilary Calvert, Alberto Costa and Bengt Glimelius at the 35th ESMO Congress, to take place from 8-12 October in Milan, Italy...

Death At Home Less Distressing For Cancer Patients And Families

Posted: September 16th, 2010, 6:00am CDT

Cancer patients who die in the hospital or an intensive care unit have worse quality of life at the end-of-life, compared to patients who die at home with hospice services, and their caregivers are at higher risk for developing psychiatric illnesses during bereavement, according to a study by researchers at Dana-Farber Cancer Institute...

Protein Clamps Tight To Telomeres To Help Prevent Aging...and Support Cancer

Posted: September 16th, 2010, 6:00am CDT

The number of times our cells can divide is dictated by telomeres, stretches of DNA at the tips of our chromosomes. Understanding how telomeres keep our chromosomes and by extension, our genomes intact is an area of intense scientific focus in the fields of both aging and cancer...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/16/3rd_Annual_Oncology_Market___Patient_Access_Conference__December_13th_14th_2010__Barcelona'

3rd Annual Oncology Market & Patient Access Conference, December 13th-14th 2010, Barcelona

Posted: September 16th, 2010, 5:00am CDT

Implementing Innovative Pricing & Reimbursement Schemes for High-Value Oncology Treatments This conference and networking event will present a fresh and original perspective on communicating the value and cost-effectiveness of high-value oncology drugs with payers, HTA assessors and other key stakeholders...

Glass Industry Honors Researcher Who Helped Make Liver Cancer More Treatable

Posted: September 16th, 2010, 5:00am CDT

Dr. Delbert Day, Curators' Professor emeritus of materials science and engineering at Missouri University of Science and Technology, has been named the 2010 Phoenix Award Glass Person of the Year, the glass industry's top honor. The Phoenix Award is given annually to a living person who has made outstanding contributions to the industry...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/16/Gentel_Launches_Thirteen_APiX%e2%84%a2_Human_Tumor_Profiling_Kits_To_Support_Cancer_Focused_Protein_Biomarker_Research'

Gentel Launches Thirteen APiX™ Human Tumor Profiling Kits To Support Cancer-Focused Protein Biomarker Research

Posted: September 16th, 2010, 4:00am CDT

Gentel Biosciences, a leader in proteomics profiling tools, announces the availability of thirteen APiX™ Human Tumor Profiling Kits, robust tissue-lysate (reverse-phase) protein arrays and chromogenic-based detection reagents, suitable for the testing of putative protein biomarkers in over thirteen cancer subtypes...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/16/Provectus_Pharmaceuticals_Completes_Initial_Enrollment_In_Phase_1_Trial_Of_PV_10_For_Liver_Cancer'

Provectus Pharmaceuticals Completes Initial Enrollment In Phase 1 Trial Of PV-10 For Liver Cancer

Posted: September 16th, 2010, 4:00am CDT

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/16/In_The_Fast_Lane__Shorter_Treatment_Times_For_Cancer_Patients_With_Increased_Speed__Power_And_Precision_Of_Radiation_Therapy'

In The Fast Lane: Shorter Treatment Times For Cancer Patients With Increased Speed, Power And Precision Of Radiation Therapy

Posted: September 16th, 2010, 4:00am CDT

On Thursday, Sept. 16, the Stanford Cancer Center will become the first treatment center on the West Coast and the fifth in the world to offer cancer patients the TrueBeam, a machine that represents an exponential leap forward in the speed, power and precision of radiation therapy...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/16/Identification_Of_Molecule_That_Increases_Survival_Of_Stomach_Cancer_Patients'

Identification Of Molecule That Increases Survival Of Stomach Cancer Patients

Posted: September 16th, 2010, 2:00am CDT

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesus Garcia-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra...

Construction Of 'Artificial Ovary' To Develop Oocytes Into Mature Human Eggs

Posted: September 16th, 2010, 2:00am CDT

Researchers at Brown University and Women & Infants Hospital have invented the first artificial human ovary, an advance that provides a potentially powerful new means for conducting fertility research and could also yield infertility treatments for cancer patients. The team has already used the lab-grown organ to mature human eggs...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/15/Routine_Population_Prostate_Screening_Not_Recommended__Single_Test_At_60_Perhaps'

Routine Population Prostate Screening Not Recommended, Single Test At 60 Perhaps

Posted: September 15th, 2010, 9:00am CDT

Researchers have found that according to existing evidence from randomized controlled trials, routinely screening large populations of men for prostate cancer is not recommended. Their report appears in today's issue of the BMJ (British Medical Journal)...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/15/Radiation_Exposure_Poses_Similar_Risk_Of_First_And_Second_Cancers_In_Atomic_Bomb_Survivors'

Radiation Exposure Poses Similar Risk Of First And Second Cancers In Atomic Bomb Survivors

Posted: September 15th, 2010, 8:00am CDT

It is well known that exposure to radiation has multiple harmful effects - including causing cancer - but until now, it has been unclear to what extent such exposure increases a person's risk of developing more than one cancer...

Flora's Fabulous Family Jumps At The Chance To Help Beat Cancer

Posted: September 15th, 2010, 8:00am CDT

Mum-of-two Flora Skeates says she owes her life to cancer research after surviving bowel cancer twice within two years. That is why she is representing Cancer Research UK in a stunning new photographic exhibition to encourage people to remember the charity in their Will. Flora, 35, of Virginia Water, was 28 when she was first diagnosed with bowel cancer in 2003...

Calcium Deposits Could Improve Breast Cancer Diagnosis

Posted: September 15th, 2010, 8:00am CDT

Scientists have discovered for the first time that studying calcium deposits in the breast, often detected through screening, could help doctors diagnose breast cancer more effectively. The study*, published in the British Journal of Cancer** today (Wednesday), examined the relationship between the composition of these deposits found in breast tissue and the malignancy of a tumour...

Dana-Farber Hosting Live Twitter Chat On Head And Neck Cancers

Posted: September 15th, 2010, 7:00am CDT

The recent news that Michael Douglas has been diagnosed with stage 4 throat cancer has raised public awareness of head and neck cancer. What causes throat cancer and what are the symptoms? Are there ways to prevent or reduce the risk of throat cancer? How is the human papillomavirus (HPV) related to oral cancer? On Thursday, Sept.16, at 5 pm ET, join Dr...

Molecule Identified That Increases Survival Of Stomach Cancer Patients

Posted: September 15th, 2010, 6:00am CDT

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. JesÃºs GarcÃa-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/15/Clinical_Experts_Detail_How_They_Use_Varian_s_TrueBeam%e2%84%a2_Technology_To_Improve_The_Precision_And_Speed_Of_Cancer_Treatments'

Clinical Experts Detail How They Use Varian's TrueBeam™ Technology To Improve The Precision And Speed Of Cancer Treatments

Posted: September 15th, 2010, 5:00am CDT

Cancer treatment experts reported their experiences with early treatments using the new TrueBeam system from Varian Medical Systems (NYSE: VAR), aimed at increasing the speed and precision of radiotherapy and radiosurgery treatments...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/15/New_Anti_Cancer_Drug__Levact_R___Bendamustine___Approved_In_The_UK_For_Low_Grade_Non_Hodgkin_s_Lymphoma'

New Anti-Cancer Drug, Levact(R) (Bendamustine), Approved In The UK For Low Grade Non-Hodgkin's Lymphoma

Posted: September 15th, 2010, 4:00am CDT

Levact® (bendamustine), a new chemotherapy agent launched today by Napp Pharmaceuticals, could offer a life-line to hundreds of patients in the UK with low grade non-Hodgkin's lymphoma (NHL), for whom other licensed treatments have failed...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/15/Cyclacel_Reaches_Agreement_With_FDA_On_A_Special_Protocol_Assessment_For_Pivotal_Phase_3_Trial_Of_Sapacitabine_In_AML'

Cyclacel Reaches Agreement With FDA On A Special Protocol Assessment For Pivotal Phase 3 Trial Of Sapacitabine In AML

Posted: September 15th, 2010, 4:00am CDT

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced that it has reached agreement with the U.S...

Researchers Report That Lung Cancer Culprit Could Offer Target For Therapy

Posted: September 15th, 2010, 3:00am CDT

A tiny molecule that spurs the progression of non-small-cell lung cancer could become a player in fighting the disease, say researchers at UT Southwestern Medical Center, who published a study on how the molecule behaves in mice in the Sept. 14 issue of Cancer Cell...

Although Cancer Deaths Fall, Prevention Still Lags Behind

Posted: September 15th, 2010, 2:00am CDT

Although overall mortality from cancer is decreasing in the European Union, its incidence increased by almost 20%, from 2.1 million new cases in 2002 to 2.5 million in 2008, says a special issue [1] of the European Journal of Cancer (the official journal of ECCO - the European CanCer Organisation) on cancer prevention...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/15/Exosomal_Release_Of_Beta_Catenin_May_Explain_Why_CD82_And_CD9_Suppress_Tumor_Metastasis'

Exosomal Release Of Beta-Catenin May Explain Why CD82 And CD9 Suppress Tumor Metastasis

Posted: September 15th, 2010, 2:00am CDT

Researchers reveal a new way in which cells restrain beta-catenin and potentially suppress tumor metastasis: the protein can be ejected from cells in small vesicles called exosomes. The study appears online in the Journal of Cell Biology. Beta-catenin is a central component of the Wnt signaling pathway that controls cell proliferation and differentiation...

Inhibiting Jak2 To 'Hi-JAK' Cancer

Posted: September 15th, 2010, 2:00am CDT

Myeloproliferative neoplasms (MPN) comprise a family of blood cancers characterized by clonal expansion of a single blood cell type. Untreated, these cancers can progress to bone marrow failure and acute myeloid leukemia. Several groups have identified activating mutations in the JAK2 gene as associated with MPN; JAK2 inhibition has therefore emerged as approach to MPN therapy...

News From The Journal Of Clinical Investigation: Sept. 13, 2010

Posted: September 15th, 2010, 2:00am CDT

DEVELOPMENT Lack of cell movement links 4 developmental disorders Kallmann syndrome is a developmental disorder characterized by hypogonadotropic hypogonadism (absence or defective function of the testes or ovaries) and a defective sense of smell as a result of an absence of olfactory bulbs, a condition known as arrhinencephaly...

Tumor Growth Suppressed By Selective Inhibition Of BMK1

Posted: September 15th, 2010, 2:00am CDT

A study describing a newly developed pharmacological inhibitor is providing detailed insight into how an enzyme that has been implicated in multiple human malignancies regulates a known tumor suppressor. The research, published by Cell Press in the September 14th issue of the journal Cancer Cell, may have broad application for treating human cancers...

How A Sponge And A Piece Of String Could Help Prevent Oesophageal Cancer

Posted: September 14th, 2010, 8:00am CDT

Researchers from the Medical Research Council (MRC) have developed a new test, called the 'Cytosponge', which can diagnose a disease known as Barrett's oesophagus. By catching this pre-cancerous condition early it may be possible to prevent a type of cancer of the oesophagus, the sixth most common cause of death from cancer in the UK...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/14/Selected_Updates_Of_Largest__Most_Comprehensive_Report_On_Cancer_Prevention_Released_At_International_Conference'

Selected Updates Of Largest, Most Comprehensive Report On Cancer Prevention Released At International Conference

Posted: September 14th, 2010, 8:00am CDT

Today, at an international conference on diet, physical activity, weight and cancer prevention, two major reviews of research into the causes of colon cancer will be presented, both of which lend further support to existing recommendations for the prevention of cancer from the American Institute for Cancer Research and World Cancer Research Fund and (AICR/WCRF)...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/14/Study_Finds_Where_Patients_Die_Affects_Quality_Of_Life_And_Mental_Health_Of_Caregivers'

Study Finds Where Patients Die Affects Quality Of Life And Mental Health Of Caregivers

Posted: September 14th, 2010, 8:00am CDT

A study of patients dying of cancer and their caregivers has found that individuals who die in the hospital or intensive care unit (ICU) had a worse quality of life at the end of their lives compared to those cancer patients who died at home with hospice services. In addition, their caregivers were more likely to develop psychiatric problems while grieving...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/14/Childhood_Cancer_Survivors_Show_Sustained_Benefit_From_Common_ADHD_Medication'

Childhood Cancer Survivors Show Sustained Benefit From Common ADHD Medication

Posted: September 14th, 2010, 5:00am CDT

A medicine widely used to treat attention-deficit/hyperactivity disorder (ADHD) also provides long-term relief from the attention and behavior changes that affect many childhood cancer survivors, according to a multicenter trial led by St. Jude Children's Research Hospital investigators...

Innovative Outpatient Chemotherapy Center To Open In Brooklyn

Posted: September 14th, 2010, 5:00am CDT

Memorial Sloan-Kettering Cancer Center (MSKCC) celebrated a new outpatient chemotherapy center, which is scheduled to open later this month, pending approval from the State Department of Health...

Lung Cancer Culprit Could Offer Target For Therapy

Posted: September 14th, 2010, 4:00am CDT

A tiny molecule that spurs the progression of non-small-cell lung cancer could become a player in fighting the disease, say researchers at UT Southwestern Medical Center, who published a study on how the molecule behaves in mice in the Sept. 14 issue of Cancer Cell...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/14/AACR_Partners_With_EmergingMed_To_Link_Patients_With_Clinical_Trials_In_Connection_To_SU2C_Broadcast'

AACR Partners With EmergingMed To Link Patients With Clinical Trials In Connection To SU2C Broadcast

Posted: September 14th, 2010, 4:00am CDT

The American Association for Cancer Research (AACR) announces its collaboration with the clinical trial navigation system EmergingMed, to connect patients with clinical trials in connection to the Stand Up To Cancer (SU2C) broadcast which took place on Sept. 10, at 8 p.m. EDT & PDT / 7 p.m. CDT...

Advaxis Publishes Research On New Her2 Vaccine

Posted: September 14th, 2010, 3:00am CDT

Scientists at Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, recently had their research using ADXS31-164, a live Listeria vaccine that targets Her2, published in a leading peer reviewed journal (Shahabi, et al 2010 Cancer Gene Therapy epublished ahead of print). "It has performed quite well in a number of preclinical models...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/14/Ovarian_Cancer_Researchers_Request_Practice_Changes_To_Protect_Against_Ovarian_Cancer__Deaths_Could_Be_Reduced_50_Percent_Over_20_Years_'

Ovarian Cancer Researchers Request Practice Changes To Protect Against Ovarian Cancer (Deaths Could Be Reduced 50 Percent Over 20 Years)

Posted: September 14th, 2010, 3:00am CDT

Gynecologic oncologists with the Ovarian Cancer Research Program at Vancouver General Hospital (VGH) and the BC Cancer Agency have begun an important campaign that will reduce deaths from ovarian cancer. They are asking all BC gynecologists to change surgical practice to fully remove the fallopian tube when performing hysterectomy or tubal ligation...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/14/Xoft_Introduces_Electronic_Brachytherapy_Cancer_Treatment_Platform_At_ESTRO_Meeting'

Xoft Introduces Electronic Brachytherapy Cancer Treatment Platform At ESTRO Meeting

Posted: September 14th, 2010, 3:00am CDT

Xoft, Inc., the pioneer of localized, isotope-free radiation treatment delivered in minimally-shielded clinical settings, today announced the introduction of the Axxent® Electronic Brachytherapy, eBx™ System to physicians and distributors in Europe...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/14/Hallucinogen_Appears_Safe__May_Improve_Mood_Among_Patients_With_Advanced_Stage_Cancer_And_Anxiety'

Hallucinogen Appears Safe, May Improve Mood Among Patients With Advanced-Stage Cancer And Anxiety

Posted: September 14th, 2010, 3:00am CDT

A pilot study suggests the hallucinogen psilocybin may be feasible and safe to administer to patients with advanced-stage cancer and anxiety, with promising effects on mood, according to a report published online today that will appear in the January 2011 print issue of Archives of General Psychiatry, one of the JAMA/Archives journals...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/14/New_Data_From_Enlyton_Supports_Use_Of_An_Antigen_Directed__Cancer_Specific_Targeting_Agent_For_PET_Based_Imaging'

New Data From Enlyton Supports Use Of An Antigen-Directed, Cancer-Specific Targeting Agent For PET-Based Imaging

Posted: September 14th, 2010, 2:00am CDT

Enlyton, Ltd., announced the publication of a cancer imaging study in which Enlyton's antigen-directed, cancer-specific targeting agent demonstrated superior performance over the industry standard, 18F-FDG, in Positron Emission Tomography (PET) imaging of colorectal cancer. In the study, Enlyton's targeting agent increasingly localized in tumor, while 18F-FDG did not...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/14/Jennerex_Presents_Positive_Interim_Data_Using_JX_594_And_Sorafenib_To_Treat_Liver_Cancer'

Jennerex Presents Positive Interim Data Using JX-594 And Sorafenib To Treat Liver Cancer

Posted: September 14th, 2010, 2:00am CDT

Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/14/Debiopharm_Group%e2%84%a2_And_Aurigene_Nominate_Development_Candidate___A_Novel_Inhibitor_Of_An_Undisclosed_Oncology_Pathway'

Debiopharm Group™ And Aurigene Nominate Development Candidate - A Novel Inhibitor Of An Undisclosed Oncology Pathway

Posted: September 14th, 2010, 2:00am CDT

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/13/Low_Prostate_Specific_Antigen__PSA__Value_And_Aggressive_Screening__Negligible_Benefit_For_Older_Men__Bad_For_Quality_Of_Life'

Low Prostate-Specific Antigen (PSA) Value And Aggressive Screening, Negligible Benefit For Older Men, Bad For Quality Of Life

Posted: September 13th, 2010, 11:00am CDT

If a man aged 55 to 74 has a low PSA (prostate-specific antigen) and receives aggressive prostate cancer screening, evaluation and treatment, his chances of receiving any benefit are negligible, according to a study published in the medical journal Cancer. Pim J...

Acute Myeloid Leukemia Lintuzumab Drug Trial Discontinued

Posted: September 13th, 2010, 10:00am CDT

A Phase IIb clinical trial of lintuzumab (SGN-33) in older patients with AML (acute myeloid leukemia) was discontinued because it did not extend overall survival, Seattle Genetic, Inc., announced today. The company said it will discontinue its development program for lintuzumab. Lintuzumab is a naked monoclonal antibody which targets the CD33 antigen...

Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward

Posted: September 13th, 2010, 8:00am CDT

Researchers are now investigating whether the human reovirus, when prescribed along with chemotherapy, will provide a desperately needed "one-two punch" against ovarian cancer. The news comes during the month of September, which is National Ovarian Cancer Month...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/13/Vandetanib_Phase_II_Trial_Shows_Significant_Improvement_Of_Progression_Free_Survival_In_Patients_With_Advanced_Papillary_Or_Follicular_Thyroid_Cancer'

Vandetanib Phase II Trial Shows Significant Improvement Of Progression Free Survival In Patients With Advanced Papillary Or Follicular Thyroid Cancer

Posted: September 13th, 2010, 7:00am CDT

AstraZeneca today announced results from a phase II study evaluating the investigational drug vandetanib for the treatment of patients with locally advanced or metastatic papillary or follicular thyroid cancer. This study, ZACTHYF, showed that treatment with vandetanib significantly improved Progression Free Survival (PFS), the primary endpoint of the study, compared to placebo (Hazard Ratio=0...

Chemicals In Indoor Swimming Pools May Increase Cancer Risk

Posted: September 13th, 2010, 5:00am CDT

Swimming in indoor chlorinated pools may induce genotoxicity (DNA damage that may lead to cancer) as well as respiratory effects, but the positive health effects of swimming can be maintained by reducing pool levels of the chemicals behind these potential health risks, according to a new study published in a set of three articles online September 12 ahead of print in the peer-r...

Cancer Research UK And AstraZeneca Sign Deal To Trial First-of-Kind Cancer Drug

Posted: September 13th, 2010, 5:00am CDT

Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have reached an agreement with AstraZeneca to take compound AZD-3965 - a first-of-its-kind experimental drug to potentially treat a range of cancers- into clinical trial. AZD-3965 targets the monocarboxylate transporter 1 (MCT1)* which is essential in cell metabolism...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/13/Varian_Medical_Systems_Spotlights_TrueBeam_Treatment_System_For_First_Time_In_Europe_At_ESTRO_2010__September_12_16__Barcelona'

Varian Medical Systems Spotlights TrueBeam Treatment System For First Time In Europe At ESTRO 2010, September 12-16, Barcelona

Posted: September 13th, 2010, 5:00am CDT

Varian Medical Systems (NYSE: VAR) is spotlighting its new TrueBeam™ medical linear accelerator for fast, powerful and efficient cancer treatments at the European Society for Therapeutic Radiology and Oncology exhibition in Barcelona next week. A fully-featured TrueBeam system will be the centerpiece of Varian's booth at the annual ESTRO meeting (Booth No. 320)...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/13/College_Of_American_Pathologists_Forges_Agreement_On_Cancer_Protocol_Development_With_Canadian_And_Australasian_Associations'

College Of American Pathologists Forges Agreement On Cancer Protocol Development With Canadian And Australasian Associations

Posted: September 13th, 2010, 4:00am CDT

The College of American Pathologists (CAP) recently signed Memoranda of Understanding (MOUs) with the Canadian Association of Pathologists (CAP-ACP) and the Royal College of Pathologists Australasia (RCPA), forging a collaboration in the development of cancer datasets, also called protocols. The CAP Cancer Protocols are designed as a guideline for definitive cancer reporting...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/12/Ed_Randall_s_Fans_For_The_Cure_Charity_Launches_BLUETEMBER_Program_To_Raise_Prostate_Cancer_Awareness'

Ed Randall's Fans For The Cure Charity Launches BLUETEMBER Program To Raise Prostate Cancer Awareness

Posted: September 12th, 2010, 3:00am CDT

Ed Randall's Fans For The Cure charity is launching its first ever BLUETEMBER program with special events at cities around the country to coincide with National Prostate Cancer Awareness Month. BLUETEMBER events included a free PSA screening during the ORIOLES-YANKEES game at Yankee Stadium on September 7th...

BSD Medical's China Distributor Orders Two BSD-2000 Hyperthermia Systems

Posted: September 12th, 2010, 2:00am CDT

BSD Medical Corporation (NASDAQ: BSDM) (the "Company" or "BSD") announced today that Dalian Orientech Co. Ltd ("Orientech"), the Company's exclusive China distributor, has ordered two BSD-2000 Hyperthermia Systems (BSD-2000)...

Nucletron Spotlights Innovations During ESTRO29

Posted: September 11th, 2010, 3:00am CDT

Nucletron, a leading provider of state of the art radiotherapy solutions for cancer treatment, announced a large number of exciting innovations for precise cancer treatment that will be in the spotlight during ESTRO29 in Barcelona. The company will be showcasing the latest developments in cancer treatment solutions for both brachytherapy and external beam...

Improvement In Prediction Of Blood Clots In Cancer Patients

Posted: September 11th, 2010, 2:00am CDT

For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published in Blood, the journal of the American Society of Hematology...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/11/Special_Edition_Of_The_Hastings_Center_Report_Focuses_On_Personalized_Medicine'

Special Edition Of The Hastings Center Report Focuses On Personalized Medicine

Posted: September 11th, 2010, 2:00am CDT

Essays Title: The Prospects for Personalized Medicine Author: Shara Yurkiewicz Summary: Ten years after the release of a working draft of the human genome, major changes have made their way into medical practice, the marketplace, research, and policy. Title: Personalized Medicine's Ragged Edge Author: Leonard M...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/10/Abiraterone_Acetate_For_Metatastic_Prostate_Cancer_So_Effective_That_Phase_3_Trial_Was_Unblinded'

Abiraterone Acetate For Metatastic Prostate Cancer So Effective That Phase 3 Trial Was Unblinded

Posted: September 10th, 2010, 2:00pm CDT

Abiraterone Acetate plus prednisone was undergoing Phase 3 clinical trials on patients with metastatic advanced prostate cancer (castration-resistant prostate cancer) when an Independent Data Monitoring Committee recommended unblinding the study - this means the patients who were not receiving the Abiraterone Acetate should be offered it, Ortho Biotech Oncology Research & Devel...

AICR Once Again Welcomes Stand Up To Cancer Telecast

Posted: September 10th, 2010, 8:00am CDT

The American Institute for Cancer Research (AICR) today welcomed to the nation's airwaves a telecast aimed at increasing private support for cancer research. Now that federal funding for cancer research is effectively decreasing for the first time in decades, the need for more and better research into the disease's origins has never been greater, said AICR experts...

DNA Trick May Be Clue To Cancer Cells' Eternal Life

Posted: September 10th, 2010, 8:00am CDT

Cancer Research UK scientists have uncovered a new strategy that could be used by cancer cells to side step the body's normal safety checks and become immortal - a key step for a cancer cell - according to a study published in Nature...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/10/Seminal_Research_Linking_Obesity__Inflammation_And_Cancer_Wins_UC_San_Diego_s_Karin_The_Prestigious_Harvey_Prize'

Seminal Research Linking Obesity, Inflammation And Cancer Wins UC San Diego's Karin The Prestigious Harvey Prize

Posted: September 10th, 2010, 7:00am CDT

Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at the University of California, San Diego School of Medicine has been awarded the 2010 Harvey Prize in human health by the Technion, Israel's premier institute of technology. The prize honors Karin's seminal research linking obesity, inflammation and cancer...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/10/WHO_Regional_Meeting_In_South_East_Asia_Addresses_Antimicrobial_Resistance__Developing_Country_Access_To_Medical_Devices'

WHO Regional Meeting In South-East Asia Addresses Antimicrobial Resistance, Developing Country Access To Medical Devices

Posted: September 10th, 2010, 7:00am CDT

During the WHO's 63rd Regional Committee Session for South-East Asia in Bangkok on Wednesday the WHO called for enhanced "efforts at the national and international level to preserve the efficacy of antimicrobial agents through the rational use of antibiotics," Indian Express reports (Thacker, 9/9)...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/10/Calif._Regulators_Seek__9.9_Bn_Fine_From_Insurer__Few_Iowans_Sign_Up_For_High_Risk_Pool__N.D._Court_Rejects_Ballot_Measure_On_Drug_Store_Ownership'

Calif. Regulators Seek $9.9 Bn Fine From Insurer; Few Iowans Sign Up For High Risk Pool; N.D. Court Rejects Ballot Measure On Drug Store Ownership

Posted: September 10th, 2010, 6:00am CDT

Reuters: "California regulators are seeking fines of up to $9.9 billion from a unit of health insurer UnitedHealth Group Inc, citing mismanaged medical claims, failure to pay doctors and other lapses. The California Department of Insurance alleges that PacifiCare violated state law nearly a million times from 2006 to 2008 after it was purchased by UnitedHealth, the largest U.S...

Image Analysis Project Aims To Classify Characteristics Of Skin Cancer

Posted: September 10th, 2010, 5:00am CDT

Melanoma-the most serious form of skin cancer-varies in size, shape and severity, and although pathologists and researchers often intuitively differentiate between types of melanomas, the variations have never been formally quantified and documented...

Lactic Acid Bacteria To Lower Risk Of Cancer

Posted: September 10th, 2010, 5:00am CDT

A small research-based Norwegian company has developed a method to reduce the formation of the carcinogenic compound acrylamide during industrial production of potatoes and coffee. International food giants are paying attention...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/10/Tengion_Adds_The_Johns_Hopkins_Hospital_As_An_Additional_Clinical_Trial_Site_For_Its_Phase_I_Neo_Urinary_Conduit%e2%84%a2_Clinical_Trial'

Tengion Adds The Johns Hopkins Hospital As An Additional Clinical Trial Site For Its Phase I Neo-Urinary Conduit™ Clinical Trial

Posted: September 10th, 2010, 5:00am CDT

Tengion, Inc., a leader in regenerative medicine, announced it has added The Johns Hopkins Hospital in Baltimore, Maryland as a second clinical trial site for its Phase I clinical trial of the Company's lead product candidate, the Tengion Neo-Urinary Conduit™, in bladder cancer patients requiring bladder removal...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/10/ImmunoCellular_Therapeutics_Announces_Long_Term_Disease_Free_Survival_Data_From_Phase_I_Study_In_Glioblastoma'

ImmunoCellular Therapeutics Announces Long-Term Disease-Free Survival Data From Phase I Study In Glioblastoma

Posted: September 10th, 2010, 4:00am CDT

ImmunoCellular Therapeutics (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. The data show six out of 16 (37...

Tracking Your PSA: Be Proactive To Find Trends

Posted: September 10th, 2010, 4:00am CDT

Experts at The University of Texas MD Anderson Cancer Center advise men to keep a record of their prostate specific antigen (PSA) test results to help determine if they are at increased risk for prostate cancer. "Recent reports have debated the usefulness of the PSA test, but men should not write off this exam," says John W. Davis, M.D...

The Safety Questioned Of Certain 'Healthful' Plant-Based Antioxidants

Posted: September 10th, 2010, 3:00am CDT

Scientists are calling for more research on the possibility that some supposedly healthful plant-based antioxidants - including those renowned for their apparent ability to prevent cancer - may actually aggravate or even cause cancer in some individuals...

Study Finds Low Liver Cancer Survival Rates Among Laotian/Hmong-Americans

Posted: September 10th, 2010, 3:00am CDT

Among Asian-Americans living in California, Laotian/Hmong-Americans have the lowest survival rates for the most common type of liver cancer, a new study by researchers with the UC Davis School of Medicine has found...

Leap Forward In Early Detection For Alzheimer's And Cancer

Posted: September 10th, 2010, 3:00am CDT

Scientists at the UK's National Physical Laboratory have developed a new strategy for quicker and more precise detection of biomarkers - proteins which indicate disease. The work could pave the way for new tools to detect early stages of Alzheimer's and cancer at the molecular level. All diseases have proteins specifically linked to them called biomarkers...

Investigating Better Endpoints For Immunotherapy Trials

Posted: September 10th, 2010, 2:00am CDT

Cancer immunotherapy calls for revised clinical endpoints that differ from those used for chemotherapy, according to an article published online in The Journal of the National Cancer Institute...

Multivitamins Don't Alter Colon Cancer Recurrence Or Death Risk

Posted: September 9th, 2010, 2:00pm CDT

Individuals with colon cancer who took multivitamins after surgery, either before, during or after chemotherapy experienced no significant change in their risk of the cancer coming back, or dying from colon cancer, wrote researchers from the Dana-Farber Cancer Institute in an article published in the Journal of Clinical Oncology...

Genetic Connection Between Endometriosis And Ovarian Cancer Found

Posted: September 9th, 2010, 10:00am CDT

A new cancer gene mutation - ARID1A - has been found which links endometriosis to two types of ovarian cancer, researchers report in an article published in the New England Journal of Medicine (NEJM)...

Abnormal Body Weight Related To Increased Mortality In Colon Cancer Patients

Posted: September 9th, 2010, 8:00am CDT

Postmenopausal women diagnosed with colon cancer may be at increased risk of death if they fail to maintain a healthy body weight before cancer diagnosis, according to a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/09/The_Pancreatic_Cancer_Action_Network_And_AACR_To_Award_Nearly__3_Million_In_Pancreatic_Cancer_Research_Grants'

The Pancreatic Cancer Action Network And AACR To Award Nearly $3 Million In Pancreatic Cancer Research Grants

Posted: September 9th, 2010, 7:00am CDT

The American Association for Cancer Research in partnership with the Pancreatic Cancer Action Network is now accepting applications for the 2011 research grants program. The program is administered using the AACR's rigorous peer-review system to ensure that the highest quality science is supported. Numerous grants will be awarded in 2011, with a total funding level of nearly $3 million...

SWOG Names Five Cancer Researchers As Outstanding Young Investigators

Posted: September 9th, 2010, 7:00am CDT

The Southwest Oncology Group, or SWOG, one of the nation's largest cancer clinical trials networks, has selected five talented researchers who are early in their careers for its 2010 Young Investigator Training Course (YITC). These five will attend a three-day workshop September 13 - 15 in Seattle, WA for intensive training in how to design and conduct cancer clinical trials...

Interdisciplinary Oncology Palliative Care Education Program

Posted: September 9th, 2010, 7:00am CDT

A multi-disciplinary team representing the schools of Medicine, Nursing and Social Work at the University of Louisville, as well as clinical pastoral education programs in three Louisville hospitals, has been awarded a grant of $1,518,092 from the National Institutes of Health that will fund the development, implementation and evaluation of an interdisciplinary oncology palliat...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/09/Cylene_To_Report_Recent_Advances_With_First_in_Class_CK2_Inhibitor__CX_4945__At_International_CK2_Conference'

Cylene To Report Recent Advances With First-in-Class CK2 Inhibitor, CX-4945, At International CK2 Conference

Posted: September 9th, 2010, 5:00am CDT

Cylene Pharmaceuticals, Inc. will report recent developments with its first-in-class, oral CK2 inhibitor CX-4945, at the 6th International Conference on Protein Kinase CK2, to be held on September 7-10 in Cologne, Germany, the company announced. CX-4945 is potentially a dynamic anticancer therapeutic, as both a stand-alone drug and for use in combination therapies...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/09/Complete_Genomics_To_Sequence_100_Genomes_For_National_Cancer_Institute_Pediatric_Cancer_Study'

Complete Genomics To Sequence 100 Genomes For National Cancer Institute Pediatric Cancer Study

Posted: September 9th, 2010, 4:00am CDT

Complete Genomics Inc., a life sciences company focused on human genome sequencing, announced a collaboration to identify and validate somatic mutations from 50 pediatric cancer cases from multiple research centers across the United States...

New Robotic Head And Neck Cancer Surgery Preserves Speech, Without Scarring

Posted: September 9th, 2010, 3:00am CDT

An incisionless robotic surgical procedure is offering patients a new option to remove certain head and neck cancer tumors without visible scarring, while preserving speech and the ability to eat. Henry Ford Hospital in Detroit is among the first in the country to perform TransOral Robotic Surgery (TORS) using the da Vinci® Surgical System...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/09/Jennerex_And_Transgene_Enter_Into_An_Exclusive_Partnership_For_The_Development_And_Commercialization_Of_JX_594_For_The_Treatment_Of_Cancers'

Jennerex And Transgene Enter Into An Exclusive Partnership For The Development And Commercialization Of JX-594 For The Treatment Of Cancers

Posted: September 9th, 2010, 3:00am CDT

Jennerex, Inc...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/09/Complex_Lung_Cancer_Treatments_Delivered_Successfully_At_Leading_Varian_Equipped_Proton_Therapy_Center'

Complex Lung Cancer Treatments Delivered Successfully At Leading Varian-Equipped Proton Therapy Center

Posted: September 9th, 2010, 3:00am CDT

Clinicians at the Rinecker Proton Therapy Center (RPTC) in Munich are reporting using advanced proton therapy systems supplied by Varian Medical Systems (NYSE: VAR) for difficult lung cancer treatments. A 75-year-old patient with a large tumor in the right upper lung received 18 proton therapy treatments over three months...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/09/CytRx_Initiates_Phase_2_Clinical_Trial_With_Bafetinib_In_Advanced_Prostate_Cancer'

CytRx Initiates Phase 2 Clinical Trial With Bafetinib In Advanced Prostate Cancer

Posted: September 9th, 2010, 3:00am CDT

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer...

Muscle Wasting In Cancer Does Not Spare The Heart

Posted: September 9th, 2010, 2:00am CDT

The wasting disease associated with some cancers that is typically seen affecting skeletal muscles can also cause significant damage to the heart, new research in mice suggests. Before now, cachexia, characterized by muscle wasting and dramatic weight loss, was believed to spare the heart...

BJGP Study Highlights Eight Early Symptoms Of Cancer

Posted: September 8th, 2010, 8:00am CDT

Eight clinical features that predict cancer at a high probability rate which could improve early diagnosis have been identified by researchers writing in this month's British Journal of General Practice (BJGP)...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/08/GWCI_Receives__2.4_Million_Grant_To_Establish_D.C._City_Wide_Patient_Navigation_Network__CPNN_'

GWCI Receives $2.4 Million Grant To Establish D.C. City-Wide Patient Navigation Network (CPNN)

Posted: September 8th, 2010, 8:00am CDT

The GW Cancer Institute (GWCI) was recently awarded a $2.4 million grant from the D.C. Cancer Consortium to establish and coordinate a City-wide Patient Navigation Network (CPNN) in Washington, D.C. The CPNN will create a seamless cohesive framework for cancer care coordination across the entire city. The CPNN will ensure that all D.C...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/08/New_Research_Confirms_Skin_Cancer_Prevention_One_Of_The_Nation_s_Best_Health_Investments'

New Research Confirms Skin Cancer Prevention One Of The Nation's Best Health Investments

Posted: September 8th, 2010, 7:00am CDT

The Australian Government should act on comprehensive new research and run an intensive SunSmart campaign to reduce Australia's unacceptable skin cancer burden, Cancer Council Australia said today...

The Risk Of Childhood Cancer Following Fetal Exposure To Radiation

Posted: September 8th, 2010, 7:00am CDT

Fetal exposure to radiation and the risk of childhood cancer: what is the likelihood of a risk? A new study published in this week's PLoS Medicine aims to evaluate the possibility that exposure of a fetus to computed tomography or radionuclide imaging performed during pregnancy might increase subsequent risk of childhood cancer...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/08/2nd_Annual_Cancer_Targets_And_Therapeutics_Conference__Oct_20_22__San_Francisco__CA'

2nd Annual Cancer Targets And Therapeutics Conference, Oct 20-22, San Francisco, CA

Posted: September 8th, 2010, 6:00am CDT

Dr. Patrick Baeuerle, Vice President of Micromet, to present as a featured speaker at GTCbio's 2nd Annual Cancer Targets and Therapeutics Conference, part of the 6th Modern Drug Discovery and Development Summit on Oct. 20-22, 2010 in San Francisco, CA. Dr. Baeuerle will give a presentation on "BiTE Antibody-Engaged T-Cells for Cancer Therapy...

Non-Hormone Treatments Can Relieve Hot Flashes In Women With Breast Cancer

Posted: September 8th, 2010, 5:00am CDT

Many women enduring hot flashes experience the heat, sweat and reddened upper body as an uncomfortable inconvenience. However, hot flashes can greatly diminish a woman's quality of life, disrupting sleep at night or causing embarrassment as she goes about her daily business. Hot flashes, called flushes in medical circles, occur commonly in women with a history of breast cancer...

Review: Helping Kids Cope With Chemo

Posted: September 8th, 2010, 5:00am CDT

Although nausea and vomiting are common in children undergoing chemotherapy, few quality studies identify absolutely the best way to prevent and treat this problem in kids, said Robert Phillips, M.D., lead author of a new Cochrane review. Phillips, a pediatric oncologist at St. James's Hospital in Leeds, England, said the main finding is the paucity of data that he and his colleagues uncovered...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/08/Chemotherapy_Drug_Does_Not_Improve_Overall_Survival_After_Resection_Of_Pancreatic_Cancer_Compared_To_More_Common_Treatment'

Chemotherapy Drug Does Not Improve Overall Survival After Resection Of Pancreatic Cancer Compared To More Common Treatment

Posted: September 8th, 2010, 4:00am CDT

Use of gemcitabine, a drug that can be effective in treating advanced and resected pancreatic cancer, did not result in improved overall survival after pancreatic cancer resection (surgical removal) compared to patients who received fluorouracil and folinic acid, another treatment regimen that has shown effectiveness, according to a study in the September 8 issue of JAMA...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/08/Prophylactic_Surgeries_Associated_With_Lower_Risk_Of_Cancer_For_Women_With_BRCA1_2_Gene_Mutations'

Prophylactic Surgeries Associated With Lower Risk Of Cancer For Women With BRCA1/2 Gene Mutations

Posted: September 8th, 2010, 4:00am CDT

Women at increased risk of breast and ovarian cancer because of inherited mutations of the BRCA1 or BRCA2 genes who had prophylactic mastectomy or salpingo-oophorectomy (removal of the fallopian tubes and ovaries) had an associated decreased risk of breast cancer and ovarian cancer, according to a study in the September 1 issue of JAMA...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/08/St._Jude_Researcher_Receives_Grant_To_Focus_On_Cancer_Pharmacogenomics_In_Children'

St. Jude Researcher Receives Grant To Focus On Cancer Pharmacogenomics In Children

Posted: September 8th, 2010, 3:00am CDT

With its new expansion of the Pharmacogenomics Research Network (PGRN), the National Institutes of Health (NIH) awarded St. Jude Children's Research Hospital a prestigious grant to focus on anticancer agent research in children. The five-year, $8.6 million grant is titled "PAAR4Kids Pharmacogenomics of Anticancer Agents Research in Children." "We've been part of the PGRN for 10 years...

Researchers Uncover Activation Signal For Aurora-A Oncogene

Posted: September 8th, 2010, 3:00am CDT

Aurora-A kinase (AurA) is an enzyme that is hyperactive in many cancers and drives tumor cell proliferation. Several AurA inhibitors are currently being tested in clinical trials to see if they slow tumor growth. Now, researchers in the Developmental Therapeutics Program at Fox Chase Cancer Center have identified an activation signal for AurA...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/08/The_Capacity_Of_4_HPR_To_Induce_Death_Of_Tumour_Cells__Applying_It_To_Acute_Lymphoblastic_Leukaemia'

The Capacity Of 4-HPR To Induce Death Of Tumour Cells, Applying It To Acute Lymphoblastic Leukaemia

Posted: September 8th, 2010, 2:00am CDT

Retinoic acid (RA), a natural derivative of vitamin A, is the basis of a number of treatments against cancer. Nevertheless, it has certain disadvantages, such as the possibility of the appearance of retinoic acid syndrome, present in 25% of cases and which can lead to death...

Scientists Create New Process To 'Program' Cancer Cell Death

Posted: September 8th, 2010, 2:00am CDT

Researchers at the California Institute of Technology (Caltech) have engineered a fundamentally new approach to killing cancer cells...

Low Carb Plant Sourced Diet Better Than Animal Sourced One

Posted: September 7th, 2010, 9:00am CDT

If you want to live longer, you are better off on a low carb diet which is vegetable based, rather than one whose proteins are sourced from animals, according to a study involving 129,716 men and women published this week in the medical journal Annals of Internal Medicine...

NHS Choices: Six Warning Signs Of Cancer

Posted: September 7th, 2010, 7:00am CDT

More than 1/3 people in the UK will develop some form of cancer during their lifetime. The good news is that some cancers can be cured if detected early enough. The key is to be aware of unexplained changes to your body, and to know the common signs and symptoms of cancer...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/07/Immutep_Announces_Final_Results_In_Phase_I_II_Chemoimmunotherapy_Trial_In_Metastatic_Breast_Cancer'

Immutep Announces Final Results In Phase I/II Chemoimmunotherapy Trial In Metastatic Breast Cancer

Posted: September 7th, 2010, 6:00am CDT

Immutep S.A. announced the publication of a clinical research paper showing that its lead product, IMP321, given with first-line paclitaxel achieved clinical benefit in 90 per cent of metastatic breast carcinoma (MBC) patients. Correlations were observed with both the patients' monocyte (i.e...

Hallucinogen Found To Safely Ease Anxiety In Advanced-Stage Cancer Patients

Posted: September 7th, 2010, 4:00am CDT

In the first human study of its kind to be published in more than 35 years, researchers found psilocybin, an hallucinogen which occurs naturally in "magic mushrooms," can safely improve the moods of patients with advanced-stage cancer and anxiety, according to an article published online in the Archives of General Psychiatry...

Poor Public Awareness Highlights Radiotherapy's 'Cinderella' Status

Posted: September 7th, 2010, 4:00am CDT

Only one in ten people know that radiotherapy helps cure forty per cent of cancer patients according to new figures* published by Cancer Research UK today (Tuesday). The survey of more than 2,000 people from across the UK also reveals just 14 per cent are aware that half of all cancer patients could benefit from radiotherapy as part of their treatment...

New Treatment Activates Death Program In Cancer Cells

Posted: September 7th, 2010, 3:00am CDT

Cancer is a difficult disease to treat because it's a personal disease. Each case is unique and based on a combination of environmental and genetic factors. Conventional chemotherapy employs treatment with one or more drugs, assuming that these medicines are able to both "diagnose" and "treat" the affected cells...

Blocking HMGB1 May Benefit Cancer Patients

Posted: September 7th, 2010, 3:00am CDT

Like some people, cells eat when they are under pressure - but they consume parts of themselves. A multi-function protein helps control this form of cannibalism, according to a study in the September 6 issue of the Journal of Cell Biology. Cells often respond to hunger or stress by digesting some of their contents...

Magic Mushroom Ingredient Psilocybin Improves Late Stage Cancer Anxiety

Posted: September 6th, 2010, 5:00pm CDT

The hallucinogen psilocybin appears to be safe and feasible to give to patients with advanced-stage cancer and anxiety - a study published in Archives of General Psychiatry reports it had a promising effect on mood. Psilocybin is the active ingredient in an illegal Class A drug in the UK called magic mushroom...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/06/First_Radiation_Oncologist_Hired_For_BC_Cancer_Agency_Centre_For_The_North_And_Appointed_To_The_Northern_Medical_Program'

First Radiation Oncologist Hired For BC Cancer Agency Centre For The North And Appointed To The Northern Medical Program

Posted: September 6th, 2010, 7:00am CDT

Dr. Robert Olson, a radiation oncologist, is the first physician to be hired for the BC Cancer Agency Centre for the North. He will be part of the provincial Radiation Therapy Program which will bring service to the North for the first time when the new centre is opened. The centre, now under construction, is expected to start treating patients by the end of 2012. Dr...

CSI Laboratories To Build New Cancer Diagnostics Laboratory In Atlanta, GA

Posted: September 6th, 2010, 7:00am CDT

CSI Laboratories®, a private national cancer diagnostic laboratory, announced the lease of a new 65,000 square foot facility in Alpharetta, GA, located north of the city of Atlanta. CSI Laboratories is committing $15 million to its strategic expansion project, and this newly leased space will house its next generation laboratory, with clinical operations beginning in mid-2011...

Celgene Officially Notified Of ANDA Filing For REVLIMID(R)

Posted: September 6th, 2010, 6:00am CDT

Celgene Corporation (NASDAQ: CELG) announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA)...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/06/Increased_Risk_Of_Second_Cancers_And_Earlier_Death_For_Childhood_Cancer_Survivors__Australia'

Increased Risk Of Second Cancers And Earlier Death For Childhood Cancer Survivors, Australia

Posted: September 6th, 2010, 5:00am CDT

Progress in childhood cancer is a good news story. Children treated for cancer have an overall 70-80 per cent cure rate. As the numbers of survivors of childhood cancer increases, studies of the long-term survivors allow research that can guide newer treatment protocols and further improve the outlook for newly diagnosed patients...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/06/More_Work_Needed_To_Implement_Evidence_Base_In_Psychooncology_In_Cancer_Care__Australia'

More Work Needed To Implement Evidence Base In Psychooncology In Cancer Care, Australia

Posted: September 6th, 2010, 5:00am CDT

An integrated approach to cancer care needs to be developed in Australia that incorporates psychosocial and biological interventions, according to an article published in a Medical Journal of Australia supplement. The Anxiety, Depression and Cancer supplement is the product of a partnership between beyondblue and the Cancer Council Australia...

Reducing Stem Cell Loss During Cancer Treatment

Posted: September 6th, 2010, 4:00am CDT

Biologists at the University of California, San Diego have discovered that a gene critical for programmed cell death is also important in the loss of adult stem cells, a finding that could help to improve the health and well-being of patients undergoing cancer treatment...

Cancer Diagnosis And Treatment Move Another Step Forward

Posted: September 6th, 2010, 4:00am CDT

Cancer diagnosis and treatment planning took another major step forward with the release of the Request for Proposals (RFP) for the purchase and installation of a second positron emission tomography/computed tomography (PET/CT) scanner at the BC Cancer Agency...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/05/Rexahn_Pharmaceuticals_Announces_Publication_Of_New_Preclinical_Research_Data_For_Novel_Anticancer_Compound_RX_8243'

Rexahn Pharmaceuticals Announces Publication Of New Preclinical Research Data For Novel Anticancer Compound RX-8243

Posted: September 5th, 2010, 3:00am CDT

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/05/Newly_Developed_Prediction_Tool_Helps_Estimate_Local_Recurrence_In_Patients_With_Non_Invasive_Breast_Cancer'

Newly Developed Prediction Tool Helps Estimate Local Recurrence In Patients With Non-Invasive Breast Cancer

Posted: September 5th, 2010, 2:00am CDT

The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. Standard treatments following surgery include radiation therapy and hormone treatment...

Acupuncture Helps Ease Side Effects And Symptoms Of Some Cancers

Posted: September 5th, 2010, 2:00am CDT

Recent studies have shown that acupuncture can help control a number of symptoms and side effects -- such as pain, fatigue, dry mouth, nausea, and vomiting -- associated with a variety of cancers and their treatments...

Using PET/CT In The Detection Of Breast Cancer Metastases

Posted: September 5th, 2010, 2:00am CDT

About one-third of women diagnosed with early-stage breast cancer will have their cancer travel, or metastasize, to other parts of the body, with the bone being the most common site of initial detectable spread...

Blood Publication Shows MLN4924 Preclinical Activity In Lymphoma

Posted: September 5th, 2010, 2:00am CDT

Millennium: The Takeda Oncology Company announced the publication of an article in the journal Blood describing the novel mechanism of action of MLN4924 through targeted pathway modulation in diffuse large B-cell lymphoma (DLBCL). MLN4924 is a small molecule inhibitor of the NEDD8-Activating Enzyme (NAE), a key component of the protein homeostasis pathway...

Peeling Back DNA Packaging To Gain Insight Into Cells

Posted: September 4th, 2010, 3:00am CDT

Scientists have built a clearer picture of how lengthy strands of DNA are concertinaed when our cells grow and divide, in a discovery could help explain how cell renewal can go wrong. Scientists have identified thousands of proteins that play a key role in compacting DNA - a crucial process by which DNA is shortened up to 10,000 times to fit inside cells as they split into two...

The Art Of Dividing

Posted: September 4th, 2010, 3:00am CDT

A basic requirement for growth and life of a multicellular organism is the ability of its cells to divide. Chromosomes in the cells duplicate and are then distributed among the daughter cells. This distribution is organized by a protein complex made up of several hundred different proteins, called the centrosome...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/04/New_Findings_May_Lead_To_The_Development_Of_More_Effective_Therapies_For_Inflammation__Wounds_And_Malignant_Tumors'

New Findings May Lead To The Development Of More Effective Therapies For Inflammation, Wounds And Malignant Tumors

Posted: September 4th, 2010, 2:00am CDT

In two closely related studies, two teams of Scripps Research Institute scientists have discovered the underlying mechanisms that activate a type of immune cell in the skin and other organs. The findings may lead to the development of new therapies to treat inflammation, wounds, asthma, and malignant tumors...

Cancer-Causing Gene Found To Be Crucial In Stem Cell Development

Posted: September 4th, 2010, 2:00am CDT

Stem cells might be thought of as trunks in the tree of life. All multi-cellular organisms have them, and they can turn into a dazzling variety other cells - kidney, brain, heart or skin, for example...

Important Breakthrough In Origins Of Aggressive Breast Cancer

Posted: September 3rd, 2010, 10:00am CDT

Researchers have made a major breakthrough in finding out how aggressive cancers originate, raising hope of novel targeted therapies for future breast cancer patients, according to a study published in the peer-reviewed journal Cell Stem Cell...

Need For Cancer Information And Support Expected To Double, UK

Posted: September 3rd, 2010, 9:00am CDT

Macmillan Cancer Support and Boots UK today officially launched a groundbreaking new three-year partnership, which aims to help provide the two million people living with cancer, and their family and friends, increased access to the information and support they need - when they need it, where they need it...

Celsion Receives SBIR Grant To Expand Its Technology Platform

Posted: September 3rd, 2010, 7:00am CDT

Celsion Corporation (Nasdaq: CLSN), a biotechnology drug development company, announced that it has been awarded a competitive Phase I Small Business Innovation and Research (SBIR) grant from the National Institutes of Health (NIH), to support the proposal, "New Thermal Sensitive Carboplatin Liposomes for Cancer"...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/03/Cancer_Drug_Model_Could_Be_A_Potential_Treatment_For_Alzheimer_s___Alzheimer_s_Society_Comment'

Cancer Drug Model Could Be A Potential Treatment For Alzheimer's - Alzheimer's Society Comment

Posted: September 3rd, 2010, 7:00am CDT

Treatments modelled on the cancer drug Gleevec could potentially prevent the formation of amyloid plaques - one of the major hallmarks of Alzheimer's disease according to a study. Treatments modelled on the cancer drug Gleevec could potentially prevent the formation of amyloid plaques - one of the major hallmarks of Alzheimer's disease according to a study published in the journal Nature...

Drug Discovery Tools To Fight Cancer, Blindness To Be Discussed At UB Symposium

Posted: September 3rd, 2010, 7:00am CDT

Twenty-first-century pharmaceutical breakthroughs require 21st-century drug discovery tools, such as computational or in silico molecular design and high-throughput screening of effective, new compounds. That's the theme of a University at Buffalo symposium to be held Sept...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/03/Imec_European_Collaborative_Research_To_Develop_Lab_on_chip_System_For_Cheap_And_Fast_Cancer_Diagnosis'

Imec European Collaborative Research To Develop Lab-on-chip System For Cheap And Fast Cancer Diagnosis

Posted: September 3rd, 2010, 5:00am CDT

Today, at the Engineering in Medicine and Biology Conference (EMBC) in Buenos Aires (Argentina), imec and its project partners have announced the launch of the European Seventh Framework Project MIRACLE. The MIRACLE project aims to develop an operational lab-on-chip for the isolation and detection of circulating and disseminated tumor cells (CTCs and DTCs) in blood...

Near Infrared Light May Open New Frontier In Fighting Cancer, Tay-Sachs

Posted: September 3rd, 2010, 5:00am CDT

A "game-changing" technique using near infrared light enables scientists to look deeper into the guts of cells, potentially opening up a new frontier in the fights against cancer and many other diseases. University of Central Florida chemists, led by Professor Kevin Belfield, used near infrared light and fluorescent dye to take pictures of cells and tumors deep within tissue...

Connection Between Light At Night (LAN) And Cancer Revealed

Posted: September 3rd, 2010, 4:00am CDT

A new study from the Center for Interdisciplinary Chronobiological Research at the University of Haifa has found an additional link between Light At Night (LAN) and cancer. This research joins a series of earlier studies carried out at the University of Haifa that also established the correlation...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/03/Afferent_Pharmaceuticals_Presents_Data_Supporting_Use_Of_P2X3_Antagonists_In_Reducing_Bone_Cancer_Pain'

Afferent Pharmaceuticals Presents Data Supporting Use Of P2X3 Antagonists In Reducing Bone Cancer Pain

Posted: September 3rd, 2010, 4:00am CDT

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecules that target P2X3 receptors, announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist significantly prevented and reversed bone cancer pain behavior in comparison to vehicle controls...

Asuragen's Clinical Laboratory Launches KRAS And BRAF Mutation Testing

Posted: September 3rd, 2010, 4:00am CDT

Asuragen, Inc., a leader in molecular diagnostics and nucleic acid-based pharmacogenomics services, announced that it has launched KRAS and BRAF mutational testing services in its CAP-accredited CLIA laboratory...

Common Osteoporosis Drug Linked To Higher Risk Of Oesophageal Cancer

Posted: September 3rd, 2010, 4:00am CDT

A new UK study that followed a large number of people found that those who took 10 or more prescriptions for oral bisphosphonates, a group of drugs commonly used to treat the bone disease osteoporosis, were at higher risk of developing oesophageal cancer...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/03/Molecular_Imaging_s_Benefits_In_The_Evaluation_And_Successful_Treatment_Planning_For_A_Wide_Spectrum_Of_Diseases'

Molecular Imaging's Benefits In The Evaluation And Successful Treatment Planning For A Wide Spectrum Of Diseases

Posted: September 3rd, 2010, 3:00am CDT

A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/03/Chromosomal_Rearrangement__Gene_Copy_Number_Methods_Featured_In_Cold_Spring_Harbor_Protocols'

Chromosomal Rearrangement, Gene Copy Number Methods Featured In Cold Spring Harbor Protocols

Posted: September 3rd, 2010, 3:00am CDT

A cell devotes a significant amount of effort to maintaining the stability of its genome, preventing the sorts of chromosomal rearrangements characteristic of many cancers. Assays that measure the rate of gross chromosomal rearrangements (GCRs) are needed in order to understand the individual genes and the different pathways that suppress genomic instability...

Cancer Patients Pay The Price To Keep Warm , UK

Posted: September 3rd, 2010, 3:00am CDT

With temperatures set to plummet below freezing across the UK this week, leading cancer charity Macmillan Cancer Support is warning that keeping warm will be even harder for cancer patients undergoing treatment, as they are already twice as likely to fall into fuel poverty as the general population 1 ...

Macmillan's Response To NICE Decision On Liver Cancer Drug

Posted: September 3rd, 2010, 3:00am CDT

Responding to the decision by the National Institute for Health and Clinical Excellence (NICE) not to recommend sorafenib (Nexavar®) as a treatment for advanced liver cancer, Mike Hobday, Head of Campaigns at Macmillan Cancer Support, said: 'We are extremely disappointed that NICE has decided not to recommend sorafenib as a treatment for people with advanced liver cancer...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/03/Novel_Nanotechnology_Collaboration_Leads_To_Breakthrough_In_Cancer_Research'

Novel Nanotechnology Collaboration Leads To Breakthrough In Cancer Research

Posted: September 3rd, 2010, 2:00am CDT

One of the most difficult aspects of working at the nanoscale is actually seeing the object being worked on. Biological structures like viruses, which are smaller than the wavelength of light, are invisible to standard optical microscopes and difficult to capture in their native form with other imaging techniques...

RNAi Screening Used For The First Time To Study Ewing's Sarcoma

Posted: September 3rd, 2010, 2:00am CDT

The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets, according to a scientific paper by the Translational Genomics Research Institute (TGen) published in the journal Molecular Cancer...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/03/Immune_System_Finding_May_Lead_To_New_Ways_To_Detect__Diagnose_And_Treat_Cancer_And_Other_Diseases'

Immune System Finding May Lead To New Ways To Detect, Diagnose And Treat Cancer And Other Diseases

Posted: September 3rd, 2010, 2:00am CDT

When it comes to the mechanics of the human immune system, we are all more alike than previously thought, according to a new study by scientists at Fred Hutchinson Cancer Research Center. This finding has significant implications for developing new ways to detect, diagnose and treat cancer and diseases of the immune system, according to Harlan Robins, Ph.D...

News From The Journal Of Clinical Investigation: Sept. 1, 2010

Posted: September 3rd, 2010, 2:00am CDT

INFECTIOUS DISEASE: Modified adenovirus malaria vaccine works a treat in mice Malaria kills more than 1 million individuals each year. Despite intensive research, there is still no malaria vaccine approved for use. A team of researchers, led by Moriya Tsuji, at the Aaron Diamond AIDS Research Center, New York, has now designed a new vaccine that provides protection from malaria in mice...

Macmillan Responds To The New Energy Bill Announced In The Queen's Speech, UK

Posted: September 2nd, 2010, 8:00am CDT

Responding to the new energy bill announced in the Queen's Speech, Mike Hobday, Head of Campaigns at Macmillan Cancer Support said: 'Whilst the mandatory support from energy companies will help some vulnerable people struggling with their fuel bills, it is vital that cancer patients are not left out in the cold...

Diabetes 2 Drug Metformin May Protect Against Lung Cancer In Smokers

Posted: September 2nd, 2010, 8:00am CDT

Two studies reveal that smokers may have a significantly lower risk of developing lung cancer and colorectal cancer with the drug metformin, which is commonly prescribed for diabetes type 2 treatment, the medical journal Cancer Prevention Research informs...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/02/Today_s_Opinions__Pawlenty_s_Order_Against_The_Health_Overhaul__Repealing_The_Health_Law_And_More_About_Health_Care_Costs'

Today's Opinions: Pawlenty's Order Against The Health Overhaul, Repealing The Health Law And More About Health Care Costs

Posted: September 2nd, 2010, 7:00am CDT

Pawlenty's Order Pure Politicking The Bemidji (Minn.) Pioneer The move can be explained in no other way than in being a totally partisan decision, intended to shore up his conservatism in what will be a 2012 battle of who is more conservative to wear the Republican mantle for president (9/1)...

Trial To Test Experimental Drug For Advanced Pancreatic Cancer

Posted: September 2nd, 2010, 6:00am CDT

Cancer Research UK's Drug Development Office has launched a clinical trial* to test an experimental drug in patients with advanced (Stage IV) pancreatic cancer - one of the most difficult cancers to treat. Around 60 patients with advanced pancreatic cancer will be recruited for the first Phase I/IIclinical trial of a drug called MK-0752** in this disease...

New Evidence That Fat Cells Are Not Just Dormant Storage Depots For Calories

Posted: September 2nd, 2010, 6:00am CDT

Scientists are reporting new evidence that the fat tissue in those spare tires and lower belly pooches - far from being a dormant storage depot for surplus calories - is an active organ that sends chemical signals to other parts of the body, perhaps increasing the risk of heart attacks, cancer, and other diseases...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/02/Cancer_Center_To_Be_The_First_In_Europe_To_Install_A_CyberKnife_VSI_System__The_Latest_Generation_Of_The_CyberKnife_System'

Cancer Center To Be The First In Europe To Install A CyberKnife VSI System, The Latest Generation Of The CyberKnife System

Posted: September 2nd, 2010, 5:00am CDT

Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced that the first CyberKnife VSI System to be installed in Europe was placed at the Leon-Berard Cancer Multidisciplinary Center (CLB) in Lyon, France. The CyberKnife VSI System is the newest addition to the CyberKnife product family...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/02/Agensys__An_Affiliate_Of_Astellas__Announces_Initiation_Of_Phase_I_Clinical_Trial_Of_AGS_16M8F_For_Renal_Cancer'

Agensys, An Affiliate Of Astellas, Announces Initiation Of Phase I Clinical Trial Of AGS-16M8F For Renal Cancer

Posted: September 2nd, 2010, 4:00am CDT

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/02/Open_House_At_Gulf_Coast_Cancer_Treatment_Center_Introduces_Elekta_Synergy%c2%ae_To_Community'

Open House At Gulf Coast Cancer Treatment Center Introduces Elekta Synergy® To Community

Posted: September 2nd, 2010, 4:00am CDT

Gulf Coast Cancer Treatment Center, the area's only American College of Radiology-accredited radiation oncology center, introduces the Elekta Synergy system. The new technology will be showcased at the center's Open House on Thursday, September 16, 2010 from 1 p.m. to 7 p.m. Gulf Coast Cancer Treatment Center (GCCTC) is located at 2100 State Avenue in Panama City. Radiation oncologists Dr. D.B...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/02/Radiation_Oncology_Services_Of_America__Inc._To_Work_With_Washington_University_On_Quality_Assurance_Initiative'

Radiation Oncology Services Of America, Inc. To Work With Washington University On Quality Assurance Initiative

Posted: September 2nd, 2010, 4:00am CDT

Radiation Oncology Services of America, Inc. (ROSA), a subsidiary of Ambulatory Services of America, Inc. (ASA), announced that it has entered into an agreement with the Department of Radiation Oncology at the Washington University in St. Louis School of Medicine to embark on a Cooperative Quality Assurance Project...

Michael Douglas Says He Has Stage Four Throat Cancer

Posted: September 2nd, 2010, 4:00am CDT

Michael Douglas told a US television audience on Tuesday night that he has been diagnosed with and is receiving treatment for stage four throat cancer. Speaking on David Letterman's "Late Show" to promote the release of his new film "Wall Street: Money Never Sleeps", the 65- year old American actor and producer said his doctors had told him he has an 80 per cent chance of survival...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/02/European_Collaborative_Research_To_Develop_Lab_on_chip_System_For_Cheap_And_Fast_Cancer_Diagnosis'

European Collaborative Research To Develop Lab-on-chip System For Cheap And Fast Cancer Diagnosis

Posted: September 2nd, 2010, 3:00am CDT

Detection of circulating and disseminated tumor cells in blood is a promising methodology to diagnose cancer dissemination or to follow up cancer patients during therapy. Today, the detection analyses of these cells are performed in medical laboratories requiring labor intensive, expensive and time-consuming sample processing and cell isolation steps...

Microsoft Excel-based Algorithm Predicts Cancer Prognosis

Posted: September 2nd, 2010, 3:00am CDT

Using readily available computer programs, researchers have developed a system to identify genes that will be useful in the classification of breast cancer. The algorithm, described in BioMed Central's open access Journal of Experimental & Clinical Cancer Research will enable researchers to quickly generate valuable gene signatures without specialized software or extensive bioinformatics training...

Nanobiotechnology To Fight Cancer And Other Illnesses

Posted: September 2nd, 2010, 2:00am CDT

Two new groundbreaking scientific papers by researchers at UC Santa Barbara demonstrate the synthesis of nanosize biological particles with the potential to fight cancer and other illnesses. The studies introduce new approaches that are considered "green" nanobiotechnology because they use no artificial compounds...

Battling Cancer: New Infrared Light May Open New Frontier In The Fight

Posted: September 2nd, 2010, 2:00am CDT

A "game-changing" technique using near infrared light enables scientists to look deeper into the guts of cells, potentially opening up a new frontier in the fights against cancer and many other diseases. University of Central Florida chemists, led by Professor Kevin Belfield, used near infrared light and fluorescent dye to take pictures of cells and tumors deep within tissue...

St. Jude Doctors And Scientists Team Up To Fight Childhood Cancer

Posted: September 2nd, 2010, 2:00am CDT

Survival rates overall for childhood cancer are almost 80 percent a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age. While September is Childhood Cancer Awareness Month nationwide, at St...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/01/Eisai_Announces_Extension_Of_FDA_Review_Of_Drug_Application_For_Investigational_Agent_Eribulin_Mesylate'

Eisai Announces Extension Of FDA Review Of Drug Application For Investigational Agent Eribulin Mesylate

Posted: September 1st, 2010, 8:00am CDT

Eisai Inc. announced today that it has received notification from the U.S...

Permalink for 'Medical_News_Today___Cancer_Oncology_News/2010/09/01/Plentiful_And_Varied_Vegetable_Consumption_Lowers_Lung_Cancer_Risk_Considerably'

Plentiful And Varied Vegetable Consumption Lowers Lung Cancer Risk Considerably

Posted: September 1st, 2010, 8:00am CDT

People who consume a variety of vegetables tend to have a lower risk of developing lung cancer compared to those who don't, according to a study published in the medical journal Cancer Epidemiology, Biomarkers & Prevention, a publication of the American Association for Cancer Research...

Bladder Cancer Risk May Be Decreased By Increasing Selenium Intake

Posted: September 1st, 2010, 5:00am CDT

A common mineral may provide protection against bladder cancer. According to results of a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, selenium intake is associated with decreased risk of bladder cancer...

Preventive Surgeries Linked To Lower Risk Of Breast And Ovarian Cancer

Posted: September 1st, 2010, 3:00am CDT

Women with the inherited mutations of the BRCA1 or BRCA2 genes who had preventive (prophylactic) breast removal (mastectomy) or the removal of the fallopian tubes and ovaries (salpingo-oophorectomy) were found to have a significantly lower risk of developing ovarian and breast cancers, says a study published in JAMA (Journal of the American Medical Association), September 1st issue...

My Health News » Medical News Today - Cancer/Oncology News » September 2010

Feeds

Medical News Today - Cancer/Oncology News (291 unread)

Posted: September 30th, 2010, 8:00am CDT

Posted: September 30th, 2010, 8:00am CDT

Posted: September 30th, 2010, 7:00am CDT

Posted: September 30th, 2010, 7:00am CDT

Posted: September 30th, 2010, 7:00am CDT

Posted: September 30th, 2010, 6:00am CDT

Posted: September 30th, 2010, 6:00am CDT

Posted: September 30th, 2010, 6:00am CDT

Posted: September 30th, 2010, 6:00am CDT

Posted: September 30th, 2010, 5:00am CDT

Posted: September 30th, 2010, 4:00am CDT

Posted: September 30th, 2010, 4:00am CDT

Posted: September 30th, 2010, 4:00am CDT

Posted: September 30th, 2010, 4:00am CDT

Posted: September 30th, 2010, 3:00am CDT

Posted: September 30th, 2010, 2:00am CDT

Posted: September 30th, 2010, 2:00am CDT

Posted: September 29th, 2010, 11:00am CDT

Posted: September 29th, 2010, 11:00am CDT

Posted: September 29th, 2010, 10:00am CDT

Posted: September 29th, 2010, 9:00am CDT

Posted: September 29th, 2010, 8:00am CDT

Posted: September 29th, 2010, 8:00am CDT

Posted: September 29th, 2010, 7:00am CDT

Posted: September 29th, 2010, 6:00am CDT

Posted: September 29th, 2010, 6:00am CDT

Posted: September 29th, 2010, 6:00am CDT

Posted: September 29th, 2010, 6:00am CDT

Posted: September 29th, 2010, 5:00am CDT

Posted: September 29th, 2010, 4:00am CDT

Posted: September 29th, 2010, 4:00am CDT

Posted: September 29th, 2010, 4:00am CDT

Posted: September 29th, 2010, 4:00am CDT

Posted: September 29th, 2010, 3:00am CDT

Posted: September 29th, 2010, 3:00am CDT

Posted: September 29th, 2010, 3:00am CDT

Posted: September 29th, 2010, 3:00am CDT

Posted: September 29th, 2010, 2:00am CDT

Posted: September 29th, 2010, 2:00am CDT

Posted: September 29th, 2010, 2:00am CDT

Posted: September 29th, 2010, 2:00am CDT

Posted: September 28th, 2010, 8:00am CDT

Posted: September 28th, 2010, 7:00am CDT

Posted: September 28th, 2010, 7:00am CDT

Posted: September 28th, 2010, 5:00am CDT

Posted: September 28th, 2010, 4:00am CDT

Posted: September 28th, 2010, 3:00am CDT

Posted: September 28th, 2010, 2:00am CDT

Posted: September 28th, 2010, 2:00am CDT

Posted: September 27th, 2010, 10:00am CDT

Posted: September 27th, 2010, 5:00am CDT

Posted: September 27th, 2010, 4:00am CDT

Posted: September 27th, 2010, 4:00am CDT

Posted: September 27th, 2010, 4:00am CDT

Posted: September 27th, 2010, 4:00am CDT

Posted: September 26th, 2010, 4:00am CDT

Posted: September 26th, 2010, 3:00am CDT

Posted: September 26th, 2010, 3:00am CDT

Posted: September 26th, 2010, 3:00am CDT

Posted: September 26th, 2010, 2:00am CDT

Posted: September 26th, 2010, 2:00am CDT

Posted: September 26th, 2010, 2:00am CDT

Posted: September 26th, 2010, 2:00am CDT

Posted: September 25th, 2010, 7:00pm CDT

Posted: September 25th, 2010, 4:00am CDT

Posted: September 25th, 2010, 3:00am CDT

Posted: September 25th, 2010, 3:00am CDT

Posted: September 25th, 2010, 3:00am CDT

Posted: September 25th, 2010, 3:00am CDT

Posted: September 25th, 2010, 2:00am CDT

Posted: September 24th, 2010, 8:00am CDT

Posted: September 24th, 2010, 7:00am CDT

Posted: September 24th, 2010, 7:00am CDT